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ABSTRACT OF DISSERTATION

MECHANISM OF CANCER SELECTIVE APOPTOSIS BY PAR-4

Despite distinct dissimilarities, diverse cancers express several common
pro-tumorigenic traits. We present here evidence that the pro-apoptotic protein
Par-4 utilizes one such common tumorigenic trait to become selectively activated
and induce apoptosis in cancer cells. Elevated PKA activity noted in cancer cells
activated the apoptotic function of ectopic Par-4 or its SAC domain, which
induces apoptosis selectively in cancer cells and not in normal or immortalized
cells. PKA preferentially phosphorylated Par-4 at the T155 residue within the
SAC domain in cancer cells. Moreover, pharmacological-, peptide- or siRNAmediated inhibition of PKA activity in cancer cells resulted in abrogation of both
T155 phosphorylation and apoptosis by Par-4. The mechanism of activation of
endogenous Par-4 was similar to that of ectopic Par-4, and in response to
exogenous stimuli, endogenous Par-4 induced apoptosis by a PKA and phosphoT155 dependent mechanism. Enforced elevation of PKA activity in normal cells
resulted in apoptosis by the SAC domain of Par-4 in a T155-dependent manner.
Together, these observations suggest that selective apoptosis of cancer cells by

the SAC domain of Par-4 involves phosphorylation of T155 by PKA.

These

findings uncover a novel mechanism engaging PKA, a pro-cancerous activity
commonly elevated in most tumor cells, to activate the cancer selective apoptotic
action of Par-4.
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CHAPTER 1
INTRODUCTION

Apoptosis or Programmed cell death is a genetic and biochemical process
essential to metazoans. It is an evolutionarily conserved pathway that is critical in
developmental as well as adult physiological processes in multi-cellular
organisms.

During

embryonic

development,

apoptosis

is

critical

for

organogenesis and ensuring the balance of cell lineage in multi-cellular tissues.
In adult animals, apoptosis serves to maintain cellular homeostasis, protects
against abnormal cell division, intracellular crisis such as DNA damage caused
either by replicative error or external agents, protein mis-folding or ionic
imbalances, and even regulating the response to infectious agents. At any given
time in a cell, a balance between pro- and anti-apoptotic factors is maintained.
Events that alter this ratio result either in excessive apoptosis or in lack of
apoptosis, if not rectified, leads to disease conditions. Insufficient apoptosis can
manifest as cancer or autoimmunity, while accelerated cell death is evident in
acute and chronic degenerative diseases, immunodeficiency, and infertility. Here,
we discuss the role of a pro-apoptotic protein prostate apoptosis response-4
(Par-4) in the pathways of apoptosis, and its role in disease processes such as
neurodegenerative disorders and cancer.

1

Identification and Characterization of Par-4
Androgen-ablation causes apoptosis of androgen-dependent prostate
cancer cells resulting in rapid involution of the tumor and is the mainstay of
prostate cancer treatment. The effect of androgen-ablation is emulated in the rat
ventral prostate gland, which serves as an excellent model to study apoptosis
and prostate involution, by withdrawal of androgen. Several novel transcripts and
proteins are induced post-castration in the regressing prostate and inhibitors of
protein and RNA synthesis inhibit regression of the prostate, indicating that the
gene products induced by androgen ablation are necessary for apoptosis.
Importantly, the calcium channel inhibitor nifedipine causes inhibition of both
apoptosis and prostate involution after castration, indicating a role for intracellular
calcium elevation in apoptosis of the prostate. In a differential screen for genes
induced during apoptosis of prostate cancer cells, we first identified the rat
prostate apoptosis response-4 (Par-4) gene (Sells et al., 1994). Par-4 was upregulated when androgen-independent prostate cancer cells were induced to
undergo apoptosis upon treatment with a calcium ionophore ionomycin,
mimicking the increase in intracellular calcium induced by androgen ablation.
Par-4

was

also

induced

in

androgen-dependent

luminal/secretory

cell

compartment of the rat ventral prostate after castration. Interestingly, Par-4 was
not induced in other organs, such as the liver or kidneys, which express
androgen receptors but do not undergo apoptosis and involution after castration.
Moreover, the par-4 gene is not induced by growth stimulation, growth arrest or
necrosis in cell culture paradigms. Subsequent studies identified the human Par-
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4 gene, which shared a high degree of nucleotide and amino acid similarity with
the rat Par-4 gene (Diaz-Meco et al., 1996; Johnstone et al., 1996).

The par-4 gene encodes a 38 kilodalton protein and maps to human
chromosome 12q21, a region that is unstable and often deleted in pancreatic and
gastric cancer (Kimura et al., 1998; Schneider et al., 2003). The Par-4 sequence
encodes a 332 amino acid protein, containing of two putative nuclear localization
sequences in the N-terminal region and a leucine zipper domain and a nuclear
export sequence in the C-terminal portion of the protein. These domains are
100% conserved in human, rat and mouse homologs of Par-4, suggesting that
the function, localization and regulation of Par-4 is similar in all mammals. In
addition, the Par-4 protein is conserved during evolution in vertebrates (Boghaert
et al., 1997). Consistent with its pro-apoptotic function, Par-4 is highly expressed
in involuting tadpole tail. The fact that the structure and function of Par-4 are
evolutionarily conserved indicates the global significance of the apoptotic function
of Par-4.

Par-4 is widely expressed in mammalian tissues. In the normal prostate
gland, Par-4 is expressed in the mesenchyme surrounding the ventral part of the
prostate and the basal glandular epithelial cells but is absent in adjacent
differentiated ductal cells. A similar pattern is seen in epithelial cells of mammary
gland and the retina where Par-4 is undetectable in terminally differentiated cells
implying that Par-4 expression is down-regulated during differentiation.
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Interestingly, withdrawal of androgen results in massive apoptosis of the ductal
cells and this apoptotic process is mediated by Par-4 that is induced during
androgen ablation. Upon testosterone ablation caused by castration, ductal cells
undergo apoptosis, which peaks at day 3. Par-4 levels increase in ductal cells of
the rat prostate on day 1 and day 3 post castration and diminish by day 5,
suggesting that Par-4 induction is an early and transient event in apoptosis of
prostate ductal cells (Sells et al., 1994). Interestingly, the anti-apoptotic protein
Bcl-2 is normally well expressed in the ductal cells and androgen-withdrawal
significantly decreases Bcl-2 expression. Consistently, an inverse correlation
between Par-4 and Bcl-2 expression is noticed in human prostate tumors (Qiu et
al., 1999a). Par-4 but not Bcl-2 is detected in primary and metastatic prostate
tumors and in xenografts of human androgen-dependent CWR22 tumors,
whereas the androgen-independent CWR22R tumors show pockets that stain for
Bcl-2 but not Par-4. A similar inverse pattern of expression between Par-4 and
Bcl-2 was also observed in lymphocytes from acute lymphoblastic leukemia
patients (Boehrer et al., 2002).

Role of Par-4 in Inhibition of Cellular Transformation and Tumorigenesis
Evasion of apoptosis is one of the key requirements of oncogenic
transformation (Hanahan and Weinberg, 2000) and one of the ways several
cancers achieve this by down-regulating Par-4 expression. Par-4 levels are
diminished in a majority of renal cell carcinoma (RCC) specimens or RCC cell
lines relative to normal proximal renal tubular (PRT) cells within tumors or PRT
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cell lines (Cook et al., 1999). Par-4 expression is decreased in a number of
neuroblastoma cell lines (Kogel et al., 2001) and in cells of patients of acute
lymphatic leukemia and chronic lymphocytic leukemia (Boehrer et al., 2001).
Oncogenic ras, a potent oncogene involved in 40% of epithelial tumors, has been
shown to down-regulate Par-4 expression at the mRNA and protein level via the
Raf - MEK - ERK pathway (Barradas et al., 1999; Qiu et al., 1999b). Oncogenic
Ras expression promotes a potent reduction of Par-4 protein and mRNA levels
through a MEK-dependent pathway. Treatment of the cells with MEK-inhibitor
PD98059 restored the levels of Par-4. In addition, the ectopic expression of
constitutively active Raf-1 or MEK mutants but not phosphatidylinositol 3-kinase
(PI3-kinase), was sufficient to decrease Par-4 levels, suggesting that other
oncogenic pathways that utilize these molecules as intermediates can potentially
repress Par-4 to promote cellular transformation. Restoration of Par-4 levels by
ectopic expression results in reduced expression of ERK1 and ERK2 MAP
kinases (Qiu et al., 1999b). Importantly, restoration of Par-4 levels in Rastransformed cells by stable expression severely impairs colony formation in soft
agar (Barradas et al., 1999; Qiu et al., 1999b). Interestingly, it appears that the
mechanism by which Par-4 suppresses Ras-mediated cellular transformation is
independent of the mechanism by which it induces apoptosis in these cells.
Consistently, inhibition of NF-κB is essential for Par-4 to induce apoptosis
(Barradas et al., 1999; Nalca et al., 1999), and Ras/ Par-4 stably expressing cells
do not show any difference in NF-κB activity when compared to the Ras/ vector
control cells.
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Interestingly, the immunological profile of Par-4 -/- knockout mice shows
an increased proliferative response of peripheral T cells together with increased
cell cycle entry and inhibition of apoptosis, elevated NF-κB activity and
decreased JNK activity (Garcia-Cao et al., 2003) These findings suggest that
Par-4 loss or reduction contributes to the pathogenesis of lymphatic
malignancies. It remains to be seen whether the reduction of Par-4 in the Par-4 /- mice contributes to the development of other malignancies.

Further

characterization of the tumor profile of these mice should shed more light on the
role of Par-4 in tumor development, progression and metastasis.

Role of Par-4 in Neuronal Apoptosis and Neurodegenerative diseases
The role of Par-4 in neuronal function under normal and disease
conditions is an intriguing and puzzling question that is being unraveled.
Involvement of Par-4 in a variety of neuronal processes ranging from embryonic
neuronal development, synaptic transport and neurotransmitter signaling to
neurodegenerative diseases have been shown in the past few years. In the
developing mouse brain, an asymmetric distribution pattern of Par-4 expression
was observed in neuronal progenitor cells. This pattern was found to regulate
ceramide-induced apoptosis during the proliferation and differentiation of stem
cells. Neuronal stem cell apoptosis is necessary to prevent hyperproliferation of
brain tissue during embryonic mouse brain development (Bieberich et al., 2003).
This function of Par-4 is now being investigated for the use of pluripotent mouse
and human stem cells in neural transplantion as selective apoptosis by Par-4
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prevents teratoma formation and enriches for neural precursors in ES cellderived neural transplants (Bieberich et al., 2004).

Par-4 is expressed in neurons in the adult mouse brain. Interestingly, Par4 was localized in the dentrites and the post-synaptic compartments of the
synaptosome rather than the cell body of the neuron. Neurons of the cerebral
cortex and the hippocampus, but not the cerebellum accumulate Par-4 in the
synaptic region (Guo et al., 2001b). The post-synaptic compartment is enriched
with cytoskeletal, transport and signaling machinery and is considered the central
region involved in the modulation of neuronal signal transduction. The positioning
of Par-4 in this region is intriguing, and it remains to be seen whether Par-4 has a
functional role in the synaptosome under normal non-apoptotic conditions. In
neurodegenerative diseases, on the other hand, there seems to be a connection
between the synaptic localization of Par-4 and apoptosis. A recent study using an
amylotrophic lateral sclerosis (ALS) mouse model identifies the synapse as a
crucial cellular site for the cell death promoting actions of Par-4 in motor neurons.
Accumulation of Par-4 in synaptosomes and post-synaptic density from the
ventral horn of the spinal cord increased as the disease progressed and
mediated production of pro-apoptotic cytosolic factors (Xie et al., 2005).

The involvement of Par-4 in neuronal apoptosis in neurodegenerative
disease is well established. Elevated levels of Par-4 mRNA and protein have are
responsible for apoptosis in dying neurons in patients, animal models and cell
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culture models of a variety of neurodegenerative conditions such as Alzheimer’s,
Parkinsons, Huntington’s diseases, amyotrophic lateral sclerosis (ALS) and
ischemic brain injury or stroke (El-Guendy and Rangnekar, 2003; Mattson et al.,
1999). For example in Alzheimer’s disease patients, an 8 to 20 fold increase in
the Par-4 protein levels was observed in hippocampal tissues and the inferior
parietal cortex compared to normal samples (Guo et al., 1998; Xie et al., 2001).
Exposure of primary neurons to apoptotic insults such as amyloid β-peptide,
Neuronal growth factor (NGF) withdrawal or oxidative insults caused a rapid and
significant increase in endogenous Par-4 levels leading to apoptosis of the cells
{Guo, 1998 #85}. An interesting feature of Par-4 mediated neuronal apoptosis is
that the mechanism involves loss of mitochondrial membrane potential leading to
activation of downstream caspases. This mechanism of apoptosis by Par-4 is not
commonly observed in the non-neuronal epithelial or fibroblast cell models tested
in our laboratory indicating tissue-specific variation in mechanism of Par-4 action.
Inhibition of Par-4 expression or function using antisense and RNA interference
technology or dominant negative Par-4, respectively, abrogates apoptosis
induced by the various agents in neuronal cell culture and in vivo animal models
of diseases (Pedersen et al., 2000; Xie et al., 2005). Interestingly, in a feedback
loop that could exacerbate the neuronal damage, Par-4 has been implicated in
the abnormal processing of amyloid precursor protein (APP) and induced an
aberrant production and secretion of Aβ-(1-142) (Guo et al., 2001a). This effect
of Par-4 is inhibited by a recently identified antagonistic interaction partner in
Apoptosis-Antagonizing Transcription Factor (AATF). AATF binds to the leucine
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zipper of Par-4 and effectively inhibits aberrant Aβ production (Guo and Xie,
2004). This finding is fascinating because AATF is known to interact with DAPlike kinase (Dlk), a pro-apoptotic binding partner of Par-4 (Page et al., 1999).
Both of these proteins interact with Par-4 through the leuzine zipper domain of
Par-4. It is possible that under normal non-apoptotic conditions, antagonistic
interaction with AATF restrict the functions of both Par-4 and Dlk. When
apoptosis is induced, Dlk and Par-4 are modified or activated to promote
interaction with each other and decreased affinity to AATF. The conditions that
dictate binding and the implications of interaction of AATF as well as other
proteins with the leucine zipper of Par-4 in the regulation of apoptosis as well as
functions un-related to apoptosis are discussed in a later sections. Targeted
inhibition of Par-4, by decreasing expression or using inhibitory partners such as
AATF, is currently being investigated as a neuroprotective strategy for neuron
degeneration.

Apoptosis Sensitizing Function of Par-4: Role of the Leucine Zipper and
Partner Proteins.
Although Par-4 over-expression does not induce apoptosis in normal cells,
Par-4 expression sensitizes cells to apoptosis by a wide variety of pro-apoptotic
stimuli such as growth factor withdrawal, agents that elevate intracellular Ca2+,
TNFα, UV, X-ray and gamma irradiation, or IFNγ. Inhibition of endogenous Par-4
protein levels by treatment with antisense or siRNA against Par-4 or functional
interruption of Par-4 using a dominant negative Par-4 mutant abrogates
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apoptosis by these apoptotic agents. Various reports have indicated that Par-4
plays a sensitizing function in various cell types including epithelial cells of the
prostate, endothelial cells, neuronal cells, transformed fibroblasts and a variety of
carcinomas. In its apoptosis-sensitizing role in these diverse cell backgrounds,
Par-4 inhibits several pro-survival pathways, activates pro-apoptotic proteins and
binds to several different partner proteins of varying function. The leucine zipper
of Par-4 is the functional domain that is key to sensitization to apoptotic stimuli
and is required for Par-4 to interact with a wide variety of proteins such as WT-1,
atypical PKCs, p62, DLK/ZIP kinase, and THAP1; deletion of the leucine zipper
domain abrogates this function of Par-4 (Fig 1.1). The leucine zipper domain
functions as a kind of sensor to signaling pathways and regulates the apoptotic
function of Par-4 by interacting with the appropriate partner protein.

Par-4 down-regulates the anti-apoptotic protein Bcl-2. The bcl-2 gene was
first identified in the t(14:18) translocation breakpoint from human follicular B cell
lymphoma (Kimura et al., 1998; Reed et al., 1996). Bcl-2 has been found to be
over-expressed in androgen independent prostate cancer. Over-expression of
Bcl-2 enables prostate cancer cells to resist apoptosis induced by androgenwithdrawal, physiological death inducers such as TRAIL, or chemotherapeutic
agents. (reviewed in (Bruckheimer et al., 1999). Qiu et al demonstrated that in
immortalized mouse NIH 3T3 fibroblasts and prostate cancer PC-3 cells that
over-expressed Par-4, there was a significant down-modulation of bcl-2 both at
the promoter level and the protein level and that this down-regulation of bcl-2
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was essential for Par-4 mediated apoptosis (Qiu et al., 1999a). Indeed, cotransfection of bcl-2 rescued the cells from apoptosis induced by growth factor
withdrawal. Par-4 exerts a pro-apoptotic role, augmenting chemosensitivity by
down-regulating Bcl-2, promoting disruption of mitochondrial membrane potential
and enforcing caspase-activation. It is interesting to note that in prostate cells,
bcl-2 is down-regulated by androgen withdrawal, the same signal that upregulates Par-4, suggesting that Par-4 is an important molecular component
involved in Bcl-2 down-modulation and induction of apoptosis (Qiu et al., 1999a).
A better understanding of the mechanism of repression of bcl-2 by Par-4 is now
possible with recent findings by Cheema et al. that Par-4 utilizes WT1 to bind the
bcl-2 promoter and transcriptionally down-regulate Bcl-2 expression (Cheema et
al., 2003).

WT-1 binds to and upregulates bcl-2 promoter in the androgen

independent cell line LNCaP/LN3. Co-expression of WT-1 and Par-4 leads to
leucine zipper domain mediated interaction of Par-4 with WT-1 at the bcl-2
promoter followed by repression of the bcl-2 promoter (Fig. 1.1).

WT-1 is a tumor suppressor protein frequently mutated in Wilm’s tumors, a
rare form of kidney tumor. WT-1 mediates growth arrest mediated by several
cytokines

such as IL-1 and abrogates thapsigargin-induced apoptosis.

Expression of Par-4 was able to override the WT-1 mediated abrogation of
apoptosis in prostate cancer and melanoma cells (Johnstone et al., 1996; Sells et
al., 1997). Although WT-1 is mainly expressed in the organs of the urinogenital
tract, less is known about the status of WT-1 protein in prostate cancer. As WT-1
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can differentially regulate bcl-2 depending on the availability of Par-4 and as bcl2 is often over-expressed in advanced prostate tumors, it is pertinent to study the
role of the interplay between WT-1 and Par-4 in the development of prostate
cancer.

Par-4 inhibits the pro-survival pathway activated by atypical PKCs, ζPKC
and λ/Iι PKC, by binding and inhibiting their kinase activities (Diaz-Meco et al.,
1996). aPKCs are serine/threonine kinases that positively regulate cell
proliferation and cell survival by activating transcription factors AP-1 and NF-κB,
respectively. aPKCs also block apoptosis by phosphorylating pro-apoptotic
protein FADD and preventing DISC formation. The interaction between Par-4
and ζPKC, mediated through the leucine zipper domain of Par-4 and the zinc
finger in the regulatory domain of ζPKC, induces a conformational change
leading to inhibition of ζPKC catalytic activity. Exposure to apoptotic stimuli such
as UV irradiation, ceramide or TNFα triggers the interaction between
endogenous Par-4 and endogenous ζPKC leading to a dramatic reduction of
ζPKC enzymatic activity and an increase in apoptosis. Concordantly,
replenishment of ζPKC levels by over-expression inhibits apoptosis by these
agents (Barradas et al., 1999; Diaz-Meco et al., 1996). aPKCs activate NF-κB by
functioning as IKKβ kinases. Par-4 potentiates TNFα-induced apoptosis by
inhibiting NF-κB through the blockade of the aPKC-IKK signaling cascade. It was
recently identified that aPKC and Par-4 are part of a ternary complex with an
adapter protein, p62 (Chang et al., 2002). p62 has been suggested to play a
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critical role in ζPKC-mediated NF-κB activation by recruiting ζPKC to the TNFα
signaling complex when the TNF receptor is activated by TNFα, IL-1β or other
ligands. p62 and Par-4 do not compete to bind to ζPKC but interact directly with
each other and form a ternary complex with ζPKC (Fig 1.1). Binding of p62 to the
ζPKC-Par-4 complex blocks Par-4 mediated inhibition of ζPKC kinase activity.
This shows that the functions of endogenous Par-4 and ζPKC are very tightly
controlled. However, little is known about the role of p62 in regulating ζPKC
activity that is not recruited to the ternary signaling complex or about the role of
p62 in the complex in the presence of diverse apoptotic signals.

Inhibition of pro-survival or anti-apoptotic pathways is not the mechanism
of action of Par-4, it also hetero-dimerizes with several pro-apoptotic molecules.
Recently the idea that Par-4 mediates apoptotic events from PML bodies or
PODs in the nucleus has emerged. In 1999, studies by Page et al. suggested
that DLK/ZIP kinase (ZIPK) bound and phosphorylated Par-4, and that this
function was essential for ZIPK mediated apoptosis (Page et al., 1999). These
findings were corroborated recently by John Reed’s group when they found that
in response to several apoptotic stimuli such as IFNγ or As2O3, ZIPK associated
with the pro-apoptotic protein DAXX and that the interaction of ZIPK and Par-4
enhanced this association (Kawai et al., 2003). This work suggested that in
response to IFNγ or As2O3, the ZIPK- DAXX complex is recruited to the PODs
where they activate apoptosis. siRNA-mediated knockdown of Par-4 resulted in
suppression of apoptosis induced by IFNγ and As2O3 (Fig 1.1). Adding to the
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Fig. 1.1. Interaction Partners of Par-4
One of the most well studied aspects of Par-4 is the ability of the Cterminal leucine zipper domain to interact with a multitude of partner proteins that
modulate the functions of Par-4. This figure is a schematic representation of the
known interaction partners of Par-4
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Fig. 1.1. Interaction Partners of Par-4
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complexity of the situation, a recent finding in neuroblastomas identified AATF as
an antagonistic binding protein that is capable of binding to both Par-4 as well as
DLK (Fig. 1.1). AATF binds to Par-4 through the leucine zipper, the same domain
that hetero-dimerizes with DLK (Guo and Xie, 2004). This finding provides a
mechanism by which AATF could regulate the functions of two pro-apoptotic
proteins under non-apoptotic conditions. How binding affinities between the three
proteins is altered during apoptosis needs to be further investigated. In primary
endothelial cells and human fibroblasts endogenous Par-4 colocalizes with
THAP1 within PODs (Roussigne et al., 2003). In addition, Par-4 is a component
of PML in blood vessels, a major site of PML expression in vivo. THAP1 is a
novel nuclear pro-apoptotic factor associated with PML NBs, which interacts with
the pro-apoptotic protein Par-4 and potentiates both serum withdrawal- and
TNFα-induced apoptosis (Fig. 1.1). Par-4 is recruited to PODs in endothelial cells
where PML plays a critical role. Thus, Par-4 is a global sensitizing agent, whose
functions/partners are modified in a context-specific manner.

Apoptosis by Par-4 in Cancer Cells
Par-4 over-expression is sufficient to induce apoptosis in most cancer
cells but normal primary or immortalized cells are resistant to its apoptotic action
in the absence of a second apoptotic signal. Par-4 very efficiently induces
apoptosis in all hormone independent cancer cell lines tested including lung,
pancreatic, head and neck cancers and neuroblastomas as well as transformed
cells such as Ras transformed NIH 3T3 fibroblasts (Chakraborty et al., 2001; El-

16

Guendy et al., 2003; Nalca et al., 1999). Interestingly, Par-4 is able to override
potential anti-apoptotic mechanisms such as high NF-κB activity, elevated
expression of Bcl-xL or Bcl-2 present in these cell lines. The apoptotic function
of Par-4 is also independent of the status of tumor suppressors such as p53 or
PTEN. Interestingly, in cancers that arise in organs such as the prostate or the
breast regulated by hormones such as estrogen or androgen, a unique
dichotomy of Par-4 function is noted: Par-4 efficiently kills the more advanced
hormone independent cancer cells whereas the hormone dependent cancer cells
are resistant to the action of Par-4. Par-4 induces apoptosis in androgen
independent prostate cancer cells such as PC-3 and DU-145 but not in androgen
dependent prostate cancer cells such as LNCaP, LAPC-4, MDA PCa 2a and 2b
(Chakraborty et al., 2001). Similarly, in breast cancer cells, Par-4 induces
apoptosis in estrogen independent cells such as MDA MB-231, MDA MB-435 but
is unable to do so in the estrogen dependent cells such as MCF-7 and T47D (ElGuendy et al., 2003).

The mechanism of apoptosis by Par-4 involves a unique co-parallel
activation of a pro-death pathway together with the inhibition of a pro-survival
pathway (Fig. 1.2). Par-4 activates the pro-death FasL-Fas-FADD-caspase-8
pathway by translocation of Fas and FasL to the cell membrane, and in parallel it
inhibits the key pro-survival transcriptional activity of NF-κB (Chakraborty et al.,
2001). Par-4 does not inhibit the ability of NF-κB to bind to DNA but abrogates
the transcriptional activity of NF-κB, thereby preventing the expression of NF-κB-
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Fig 1.2. Mechanism of Apoptosis by Par-4 in cancer cells.
In cancer cells, Par-4 induces apoptosis by a unique two pronged
mechanism: First Par-4 activates a pro-apoptotic system by signaling the
translocation of Fas and FasL to the cell membrane thereby activating the death
receptor mediated apoptotic pathway. At the same time Par-4 shuts down a prosurvival pathway by inhibiting NF-κB transcriptional activity.
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Fig. 1.2. Mechanism of Apoptosis by Par-4 in cancer cells
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regulated anti-apoptotic genes. As a corollary, it is interesting to note that, MEFs
derived from Par-4 -/- mice have elevated levels of NF-κB activity compared to
matched Par-4 +/+ MEFs (Garcia-Cao et al., 2003). In addition to inhibition of
NF-κB transcription Par-4, in parallel, activates the pro-death FasL-Fas-FADDcaspase-8 pathway by effecting the golgi dependent translocation of Fas and
FasL to the cell membrane (Fig. 1.2). The trafficking of Fas and FasL by Par-4
triggers the interaction of death receptor Fas and FADD that is essential for the
formation of a death-inducing signaling complex (DISC) (Chakraborty et al.,
2001). Certain cancer cells, such as acute myeloid leukemia cells, acquire
resistance to Fas induced apoptosis by phosphorylating FADD and thereby
inhibiting

DISC

formation.

It

was

recently

found

that

Par-4

inhibits

phosphorylation of FADD by inhibiting atypical PKC and promotes DISC
formation (de Thonel et al., 2001). Activation of the Fas-FADD pathway is crucial
for apoptosis by Par-4, as dominant negative or dominant interferring mutants of
Fas, FADD, or caspase-8-blocked apoptosis by Par-4. In prostate cancer cells,
the inhibition of NF-κB alone with IκB or the activation of the Fas pathway alone
is not sufficient to induce apoptosis; but when used together IκB and Fas mimic
Par-4 induced apoptosis. This implies that each pathway is necessary but not
sufficient to induce apoptosis of prostate cancer cells and that Par-4 alone
regulates both these pathways (Chakraborty et al., 2001).
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Regression of Tumors by Par-4
Consistent with its pro-apoptotic and anti-transformation role in cell culture
paradigms, Par-4 over-expression in mouse tumor models results in tumor
regression. Subcutaneous tumors generated in nude mice with PC-3 cell
implants and a single injection of adenovirus over-expressing Par-4 caused a
dramatic reduction in tumor volume in <3 weeks compared to tumors injected
with an adenovirus-producing GFP (Chakraborty et al., 2001). Stable overexpression of Par-4 decreased the development of tumors resulting from
xenotransplanted A375-C6 melanoma cells in SCID mice and this diminished
tumor growth correlated with increased tumor cell apoptosis (Lucas et al., 2001).
In addition to nude mice, Par-4 also reduced orthotopic tumors in immunocompetent mice indicating that this function of Par-4 is independent of the
immuno-deficient status of the nude mice. Intra-prostatic tumors were generated
in C57BL/6 mice by injecting syngenic prostate cancer cells RM-1 into the
prostate gland of the mice. Similar to the subcutaneous tumors, a single injection
of adenovirus expressing Par-4 caused a significant reduction in tumor volume
compared to the GFP expressing control virus demonstrating that tumor
regression is a potent function of Par-4 (J.R. Herman, 2001). The mechanism by
which Par-4 reduces in tumor size involves induction of apoptosis as assessed
by TUNEL staining of the tumors. Similar to the mechanism of apoptosis in
cancer cell cultures, regression of tumors by Par-4 is dependent on the activation
of the Fas-FADD death receptor pathway and inhibition of NF-κB pathway.
Tumors derived from cells stably expressing dn-FADD or RelA failed to show

21

regression (Chakraborty et al., 2001). Together, these findings suggest that Par4 is an ideal candidate for therapy of tumors. However, not much is known about
the role of Par-4 in two critical events of tumorigenisis including angiogenesis
and local tissue invasion leading to metastasis of tumors. In a promising
development, an in vitro study with melanoma cells suggested that Par-4
decreases migration in these cells. Over-expression of Par-4 in mouse
melanoma B16 F1 cells decreases their migration ability in a ζPKC-dependent
manner. The mechanism by which the migration was affected was not elucidated
but in the presence of low levels of ζPKC, Par-4 did not affect cell migration
(Sanz-Navares et al., 2001). It was hypothesized that in non-metastatic cells, the
ζPKC-Par-4 complex provides a brake on migration and events that prevent Par4 mediated down-regulation of ζPKC activity in melanoma cells may promote
metastasis.

Structure, Function and Localization Analysis: Identification of Selective
for Apoptosis induction in Cancer cells (SAC) domain.
Par-4 is strongly localized in the nucleus in most cancer cell lines. On the
other hand, in all the normal cells tested, over-expressed Par-4 in the absence of
another apoptotic signal is predominantly localized in the cytoplasm and does not
induce apoptosis. Concordantly, the ∆NLS2 mutant of Par-4 in which both NLS1
and NLS2 are deleted, is purely cytoplasmic and is unable to induce apoptosis
(El-Guendy et al., 2003). Intriguingly, in hormone dependent breast cancer cells
MCF-7 or prostate cancer cells LNCaP, Par-4 is purely cytoplasmic in localization
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and does not induce apoptosis. However, derivatives of these cell lines known to
be hormone independent such as MCF-7 stably expressing oncogenic Ras
(MCF-7 Ras) or LNCAP stably expressing IL-6 (LNCaP-IL-6) show nuclear
translocation of Par-4 and are susceptible to apoptosis by Par-4 (El-Guendy et
al., 2003). These findings, taken together, suggest that nuclear entry is essential
for direct apoptosis by Par-4. The mechanism by which Par-4 is excluded from
the nucleus of normal cells, estrogen dependent breast cancer cell lines or
androgen dependent prostate cancer cell lines is not known. Nuclear exclusion is
possibly a highly efficient mechanism to protect healthy cells from the apoptotic
action of Par-4, and one of the outcomes of tumor progression is probably
diminished stringency in nuclear exclusion of Par-4 in advanced cancers relative
to normal cells leading to increased nuclear presence of Par-4. Our ongoing
studies will verify whether nuclear entry is a regulatory mechanism for apoptosis
by Par-4 and identify the molecular basis for the differences underlying the
nucleocytoplasmic trafficking of Par-4 in normal and cancer cells.

A deletion mutant of Par-4 that contains amino acids 137-195, including
an intact NLS2, constitutively enters the nucleus in all normal and cancer cell
lines. The 137-195 mutant has an expanded range in inducing apoptotic killing
both hormone dependent and hormone independent cancer cell lines. In fact,
amino acids 137-195, represents a unique core domain of Par-4 that is essential
and sufficient for Fas/FasL translocation to the cell membrane, inhibition of NFκB activity and induction of apoptosis in cancer cells. Interestingly, although this
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core domain localizes to the nucleus, it does not induce apoptosis in normal cells
and was therefore designated as the domain for Selective Apoptosis-induction in
Cancer cells (SAC domain) (El-Guendy et al., 2003). This core domain is 100%
conserved in rat, mouse, and human Par-4. These findings indicate that nuclear
entry is essential but not sufficient for apoptosis by Par-4, and that Par-4 may
require additional activation events; for example, posttranslational changes in the
SAC domain; that occur selectively in cancer cells leading to induction of
apoptosis. The SAC domain resembles neither the death domains nor the death
effector domains of other pro-apoptotic proteins, nor does it show significant
homology with other known proteins in GenBank; and unlike the previously
characterized death domains and death effector domains, the SAC domain
specifically induces apoptosis in cancer cells and not normal cells. This study will
focus on identifying and characterizing the molecular differences between normal
and cancer cells that selectively activate apoptosis by the SAC domain.

Specific Aims of this study
Par-4 is a pro-apoptotic protein implicated in various physiological and
pathological apoptotic pathways. In most cancer cells, over-expressed Par-4
localizes strongly in the nucleus and spontaneously induces apoptosis in these
cells. By contrast, in normal/immortalized cells, Par-4 is predominantly
cytoplasmic and does not induce apoptosis, indicating that the nuclear presence
of Par-4 is essential for apoptosis. The minimal region of Par-4 required for
apoptosis, the SAC domain, constitutively enters the nucleus and has an
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Fig.1.3. Model for Mechanism of Spontaneous Apoptosis by Par-4
Par-4 specifically induces apoptosis in cancer cells but not normal cells.
This model suggests that mechanism for activation of apoptosis by Par-4
requires two specific events, namely, post-translational, possibly phosphorylation
event/s in the SAC domain and nuclear translocation of Par-4.
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Fig.1.3. Model for Mechanism of Spontaneous Apoptosis by Par-4
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expanded range in inducing apoptosis of all cancer cell lines tested. Interestingly,
although this mutant localizes to the nucleus, it does not induce apoptosis in nontransformed normal/immortalized cells (El-Guendy et al., 2003). These findings
indicated that besides nuclear entry, Par-4 requires additional activation event(s)
in order to induce apoptosis and that cancer cells possess the ability to activate
the SAC domain of Par-4 (Fig 1.3):

Hypothesis: Activation of apoptosis by Par-4 requires two specific events,
namely, post-translational, possibly phosphorylation event/s in the SAC domain
and nuclear translocation of Par-4 (Fig. 1.3). The specific objectives of this study
are to:
1. Identify the candidate amino acid residues in the SAC domain of Par-4 that
could be phosphorylated and establish their importance in apoptosis by site
directed mutagenesis.
2. Verify whether phosphorylation of residues S154 or T155 present in the
SAC domain are involved in activation of Par-4 function
3. Identify the kinase that phosphorylates either S154 or T155
4. Identify the mechanism behind the cancer selective activation of apoptosis
by the SAC domain; verify if the same kinase that phosphorylates either
S154 or T155 is elevated in cancers
5. Show that apoptosis by endogenous Par-4 in response to stimuli is
regulated by the same mechanism as ectopic Par-4 in cancer cells
Copyright © Sushma Gurumurthy 2005
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CHAPTER 2
MECHANISM OF CANCER SELECTIVE APOPTOSIS BY PAR-4
Introduction
Tumors often show heterogeneity at many levels including morphology,
expression of pro-survival traits and down-modulation of apoptotic or tumor
suppressor traits. Despite tumor heterogeneity, several predominant traits exist
within similar types of cancers. Such traits are prospective targets for therapeutic
intervention strategies. However, because most cancer therapy protocols have
an accompanying toxicity for normal cells, there are ongoing efforts directed
toward the identification of apoptotic molecules that are highly selective for
cancer cells. Our recent studies have identified Par-4 protein as a unique proapoptotic molecule that induces apoptosis in hormone-independent but not
hormone-dependent cancer cells or in primary or immortalized normal cells (ElGuendy et al., 2003).

We describe here a novel mechanism underlying the

selective activation of the apoptotic function of Par-4 in cancer cells.

The par-4 gene was identified in a search for genes induced during
apoptosis in prostate cancer cells (Sells et al., 1994). The gene maps to human
chromosome 12q21, a region that is unstable and often deleted in pancreatic and
gastric cancers (Schneider et al., 2003). Expression of Par-4 is diminished in
renal cell carcinoma (Cook et al., 1999), neuroblastoma (Kogel et al., 2001),
acute lymphatic leukemia and chronic lymphocytic leukemia (Boehrer et al.,
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2001). In addition, the par-4 gene is down-regulated by oncogenes such as Ras,
Raf or Src, (Barradas et al., 1999; Qiu et al., 1999b), and restoration of Par-4
levels results in the inhibition of oncogene-induced cellular transformation (Nalca
et al., 1999). Interestingly, ectopic Par-4 over-expression in cancer cells is
sufficient to induce apoptosis in these cells and cause regression of tumors.
Direct apoptosis by Par-4 occurs by a unique mechanism that involves coparallel activation of the pro-death FasL-Fas-FADD-caspase-8 pathway and
inhibition of NF-κB pro-survival pathway (Chakraborty et al., 2001). Par-4
activates the Fas pathway by inducing the translocation of Fas and FasL to the
cell membrane, and parallel inhibition of the transcription activity of NF-κB, to
allow the apoptosis pathway to progress unhindered (Chakraborty et al., 2001).
Apoptosis in cancer cells by Par-4 is independent of potential anti-apoptotic
roadblocks, such as high NF-κB activity, Bcl-xL or Bcl-2 levels, and the status of
tumor suppressors such as p53 or PTEN (Chakraborty et al., 2001).

Par-4 is a 332 amino acid protein that is composed of a leucine zipper
domain in the carboxy-terminal region and two putative nuclear localization signal
(NLS) domains (El-Guendy et al., 2003). These domains are fully conserved in
human, rat and mouse Par-4 (El-Guendy and Rangnekar, 2003). We recently
reported that nuclear localization of Par-4 by NLS2 is essential for apoptosis by
Par-4 (El-Guendy et al., 2003).

In certain cancer cells and normal or

immortalized cells, Par-4 does not enter the nucleus and is unable to induce
apoptosis (El-Guendy et al., 2003). Consistently, a deletion mutant of Par-4,
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containing amino acids 137-195 with intact NLS2 domain, constitutively enters
the nucleus and has an expanded range in inducing apoptosis of all cancer cell
lines tested (El-Guendy et al., 2003). In fact, the region containing amino acids
137-195 represents a unique core domain of Par-4 that is essential and sufficient
for Fas/FasL translocation to the cell membrane, inhibition of NF-κB activity and
induction of apoptosis in cancer cells. Interestingly, although this core domain
localizes to the nucleus, it does not induce apoptosis in normal/immortalized
cells, and was therefore designated as the domain Selective for Apoptosis
induction in Cancer cells (SAC domain) (El-Guendy et al., 2003). These findings
indicate that nuclear entry is required but not sufficient for apoptosis by Par-4,
and

that

Par-4

may

require

additional

activation

events;

such

as,

posttranslational changes in the SAC domain, that occur selectively in cancer
cells leading to induction of apoptosis.

One of the most common posttranslational modifications by which the
function of cellular proteins may be rapidly switched on or off is phosphorylation.
The phosphorylation events are affected by tyrosine or serine (S)/threonine (T)
kinases. cAMP dependent protein kinase or PKA is one such S/T kinase that is
involved in the regulation of gene expression, metabolism, cell growth and
differentiation. PKA is a broad-spectrum kinase that phosphorylates a wide
variety of substrates and is therefore very tightly regulated by differential
expression of subunits and sub-cellular localization. The PKA holoenzyme is a
tetramer composed of two catalytic (C) subunits that are held in an inactive state
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by association with regulatory (R) subunits. Binding of cAMP to the R subunits
causes the C subunits to dissociate allowing phosphorylation of substrates
(Corbin and Keely, 1977; Corbin et al., 1973; Gibbs et al., 1992; Wang et al.,
1991). PKA occurs in mammalian cells in two distinct isoforms, PKA-I and PKAII, which differ only in their regulatory subunits (that are termed RI for PKA-I and
RII for PKA-II). PKA-I is generally associated with proliferation, and is often overexpressed in human cancer cell lines and in primary tumors. On the other hand,
preferential expression of PKA-II is found in normal non-proliferating tissues and
in growth-arrested cells (reviewed in (Tortora and Ciardiello, 2002)). In addition
to the current dogma for PKA regulation, recent discoveries implicate the
existence of cAMP-independent activation of PKA (Cvijic et al., 2000).

The role of PKA in cancers is not fully understood. On the one hand,
germline mutations in PKA-I lead to the Carney complex, a multiple neoplasia
syndrome associated with a greater PKA response to cAMP due to
compensatory increases in the other PKA subunits (reviewed in (Stergiopoulos
and Stratakis, 2003)). On the other hand, PKA-I is found to be over-expressed in
several cancer cells, and is often associated with a poor prognosis in cancer
patients (Cho-Chung et al., 2002). In addition, increased expression of PKA-I is
seen following cellular transformation by certain growth factors, such as TGF-α,
or oncogenes, such as ras, myc and erbB-2 (Tortora and Ciardiello, 2002).
Although PKA is primarily an intracellular enzyme, there is growing evidence that
there is a form of PKA that is secreted into the extracellular space. Extracellular
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PKA functions in a cAMP-independent manner and the levels of this form of PKA
are especially high in the growth media of cultured cancer cells, as well as, in
plasma samples from cancer patients (Cho et al., 2000; Cvijic et al., 2000).
Furthermore, over-expression of the catalytic subunit of PKA (PKAc) in fibroblast
cells leads to transformation of the fibroblasts; this finding directly implicates PKA
in the process of oncogenesis (Wu et al., 2002). In a recent study of breast
cancer patients, elevation of PKA activity was found to be the cause of tamoxifen
resistance in breast cancer (Michalides et al., 2004). Thus, ample evidence in
literature suggests that PKA plays a critical role in the development of the cancer
phenotype. PKA exerts its cellular functions by phosphorylation of various
substrate proteins that include transcription factors such as CREB and NF-κB,
pro-apoptotic proteins such as Bad, or tumor suppressor proteins such as LKB1
(Collins et al., 2000; Harada et al., 1999; Zhong et al., 1998).

In the present study, we investigated the mechanism by which Par-4 or
the SAC domain selectively induces apoptosis in cancer cells but not in primary
normal or immortalized cells. We report that PKA-mediated phosphorylation of
T155 residue in Par-4 is essential for the apoptotic function of Par-4. Moreover,
we found that the PKA enzymatic activity is elevated in transformed and cancer
cell lines, relative to normal/immortalized cells, leading to selective activation of
the apoptotic function of Par-4 in cancer cells but not in non-transformed cells.
Thus, the pro-apoptotic molecule Par-4 utilizes elevated PKA, a pro-survival
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alteration commonly occurring in several types of cancer cells, for activation, in
order to induce selective apoptosis of the cancer cells.
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MATERIALS AND METHODS
Cell lines
Androgen-dependent prostate cancer cells LNCaP; androgen-independent
prostate cancer cells PC-3, DU145, or LNCaP/IGFBP5 (an isogenic derivative of
LNCaP); immortalized human prostate epithelial cells PZ-HPV-7; normal primary
prostatic cells PrE or PrS; mouse embryo fibroblast (MEF) cells, NIH 3T3
fibroblast cells and NIH 3T3/Ras transformed fibroblast cells; human lung cancer
cells A549, H157, H838 and H460; and human breast cancer cells MCF-7, MDA
MB 231 and MDA MB 435 have been described by us (El-Guendy et al., 2003).
Normal bronchial epithelial cells NHBE were purchased from Clonetics Corp.
(San Diego, CA). Human embryonic lung fibroblast cells HEL were from Tim
Kowalik (University of Massachusetts, Worcester, MA).

Plasmid constructs chemical reagents and antibodies.
pCB6+ vector, pCB6+-Par-4, GFP-SAC domain and GFP-137-187
constructs, and NF-κB-luciferase reporter construct were described previously
(El-Guendy et al., 2003). The S154 to 154A or T155 to 155A point mutant of
Par-4 was made by site directed mutagenesis, so as to change the sequence at
S154 from TCC to GCC or T155 from AGC to GCC.

GFP-SAC domain/155A

and GFP-137-187/155A constructs were prepared by PCR amplification using
Par-4/155A as template, followed by ligation in pcDNA3.1/CT-GFP-TOPO vector
(Invitrogen Corp., CA). The expression construct for the catalytic subunit of PKA
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(PKAc) was kindly provided by Sankar Ghosh (Yale Medical School, CT). PKA
inhibitory peptide PKI and 8-Cl-cAMP were from Calbiochem.

Vincristine,

doxorubicin and DAPI were from Sigma Chemicals Co. (St. Louis, MO).
Antibodies for Par-4, PKA, pCREB, and total CREB, as well as the Annexin V kit
for apoptosis assays were from Santa Cruz Biotechnology, Inc. (Palo Alto, CA).
The actin antibody was from Sigma Chemical Co. (St. Louis, MO). The phosphoT155-Par-4

antibody

was

raised

in

rabbits

against

the

peptide

KRKLREKRRS(PO4T)GVVNIP (representing amino acids 148-161 of Par-4 with
phosphorylated T155 residue).

Small interfering (si) RNA oligonucleotide

duplexes directed against human Par-4 or human PKA α or β catalytic subunits
were from Dharmacon, Inc. (Lafayette, Co).

Transfection and RelA/NF-κB reporter assays.
Cells were transiently transfected with the indicated plasmid constructs by
using lipofectamine-plus (from Invitrogen Life Technologies, CA) according to the
manufacturer’s instructions. Cells were harvested after 48 h, and whole-cell
lysates were resolved by SDS-PAGE, transferred to PDVF membranes and
subjected to Western blot analysis to ascertain expression of the constructs; or to
luciferase and β-galactosidase assays, to quantify and normalize NF-κB activity,
as previously described (Chakraborty et al., 2001).
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PKA activity assay.
The in vitro PKA enzymatic assay was performed using the cAMPdependent PKA Signatect Assay kit from Promega Corp. (Madison, WI). Briefly,
cells were suspended in extraction buffer (25 mM Tris-pH 7.4, 0.5 mM EDTA, 0.5
mM EGTA, 10 mM β-mercaptoethanol, leupeptin, aprotinin and PMSF) and
homogenized using a cold homogenizer.

Aliquots of cell lysate (5 µl) were

incubated with PKA assay buffer (200 mM Tris-pH7.4, 100 mM MgCl2, 0.5 mg/ml
BSA), 25 mM cAMP, PKA biotinylated substrate peptide and (γ-32P)-labeled ATP
at 30 C. After 15 minutes, the reaction was terminated with guanidinium
hydrochloride and spotted on streptavidin-coated phosphocellulose paper.
Incorporation of γ-32P into PKA biotinylated substrate peptide was measured in a
scintillation counter, and the PKA activity was normalized to protein concentration
of the cell lysates and expressed as pmoles of ATP/min/µg protein.

Apoptosis assay and indirect immunofluorescence.
Cells, plated in chamber slides, were transiently transfected with Par-4,
mutant Par-4, or PKAc constructs or subjected to the indicated treatments. The
cells were subjected to immunocytochemistry (ICC) by using Par-4 or PKA
antibody followed by secondary antibody conjugated to Alexa Fluor 488 (green
fluorescence) or Texas red (red fluorescence), and nuclei were stained with DAPI
(cyan fluorescence) and visualized by confocal microscopy. In each experiment,
a total of at least 300 transfectants expressing the constructs were scored for
apoptosis based on condensed nuclei, or by staining with FITC conjugated-
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Annexin V, (Chakraborty et al., 2001). The data presented are mean values of
three independent experiments + standard deviation.

Metabolic phospholabeling and immunoprecipitation.
Cells were transfected with expression constructs for Par-4 or the
indicated point mutants, and 36h post-transfection, the cells were washed with
phosphate-free DMEM, incubated overnight with (32P) orthophosphate (200
µCi/ml). Cells were lysed with lysis buffer (50 mM Tris-HCl-pH 7.5, 1 mM EGTA,
1 mM EDTA, 1% w/w Triton X-100, 1mM sodium orthovanadate, 50 mM sodium
fluoride, 5 mM sodium pyrophosphate, 0.27 M sucrose, 1 µM microcystin-LR,
0.1% v/v 2-mercaptoethanol, and complete proteinase inhibitor mixture) and Par4 was immunoprecipitated from the cleared lysate with anti-Par-4 antibody (5 µg
of antibody conjugated to 5 µl of protein G-Sepharose beads). The
immunoprecipitates were washed ten times with lysis buffer and subjected to
SDS-PAGE, transferred to a nylon membrane followed by autoradiography. The
same blots were subjected to Western blot analysis with anti-Par-4 antibody as a
loading control.

In vitro phosphorylation assays on immunoprecipitated Par-4.
NIH 3T3 cells were transiently transfected with Par-4 or the indicated point
mutants, the cells were lysed after 48h and Par-4 was immunoprecipitated as
described above. Kinase assays were performed in vitro by adding purified PKA
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enzyme and (γ-32P) ATP in kinase buffer (10 mM MgCl2, HEPES-pH 7.2).
Immunoprecipitated proteins were incubated in a total volume of 40µl at 30°C
with 1 units/ml PKA, in kinase (10 mM MgCl2, HEPES pH7.2), 100 µM (γ-32P)
ATP (1000 cpm/pmol). After incubation for 15 min, incorporation of phosphate
into Par-4 was determined by resolving the samples by SDS-PAGE, followed by
transfer to PVDF nylon membrane and autoradiography. The same blots were
subjected to Western blot analysis with anti-Par-4 antibody as a loading control.

Transfections with siRNA.
Cells, in six-well plates, were transiently transfected with siRNAs using
Oligofectamine (Invitrogen Corp.). Briefly, 4 µg of siRNA against Par-4 or PKA α
and β catalytic subunits or control siRNA was mixed with 175 µl of Opti-MEM
(fresh RPMI medium without antibiotics) and complexed with a mixture of 3 µl of
Oligofectamine and 15 µl of Opti-MEM for 20 min at room temperature. The
complex was diluted to obtain a final volume of 1 ml and added to the cells. After
4 h, the cells were replenished with 500 µl of Opti-MEM containing 30% fetal calf
serum and incubated for 24 h. siRNA transfections were repeated after 24 h, and
after a total of 48 h, the cells were processed for either apoptosis, PKA activity
assays

or

Western

blot

analysis..

The

siRNA

for

Par-4

(5’-

GAUGCAAUUACACAACAGAdTdT-3'); siRNA for PKA catalytic subunit α
(catalog number M-004649-00) and PKA catalytic subunit β (catalog number M004650-00) were purchased from Dharmacon, Inc., Lafayette, CO.
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RESULTS
T155 residue is essential for apoptosis by Par-4.
We recently reported that nuclear localization is essential for apoptosis by
Par-4 (El-Guendy et al., 2003). Par-4 does not enter the nucleus in normal cells
or in hormone-dependent cancer cells, such as the prostate cancer cells LNCaP
or breast cancer cells MCF-7, and is unable to induce apoptosis. Moreover when
NLS2 is deleted, Par-4 loses its ability to induce apoptosis. The SAC domain
mutant of Par-4 constitutively enters the nucleus and has an expanded range in
inducing apoptosis of all cancer cell lines tested. Interestingly, although this
mutant localizes to the nucleus, it does not induce apoptosis in non-transformed
normal/immortalized cells (El-Guendy et al., 2003). These findings indicated that
besides nuclear entry, Par-4 or the SAC domain require additional activation
event(s) in order to induce apoptosis.

To identify a potential activation switch in Par-4, we focused on the amino
acid sequence of the SAC domain, and noted the presence of two PKA
consensus phosphorylation sites at residues S154 and T155 for PKA (Fig. 2.1A).
To test the functionality of these sites, we mutated the S154 or T155 residues to
154A or 155A, respectively, in full length Par-4. The ability of these mutants to
induce apoptosis was tested in PC-3 cells, which are known to undergo
apoptosis with Par-4. The cells were transiently transfected with vector, wild type
Par-4, 154A or 155A mutant constructs and assayed for apoptosis by scoring
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Fig. 2.1. T155 is essential for the apoptotic function of Par-4.
A)

Schematic representation of NLS1, NLS2, S154, T155 and the SAC

domain of full length Par-4.
B)

PC-3 cells were transiently transfected with vector, Par-4, ∆NLS2 or the

point mutant 154A or 155A, and expression of Par-4 and mutants was examined
by Western blot analysis using the Par-4 antibody or actin antibody
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Fig. 2.1. T155 is essential for the apoptotic function of Par-4.
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Fig. 2.1. T155 is essential for the apoptotic function of Par-4.
C and D)

The ability of Par-4 or the mutants to induce apoptosis at 48 h post-

transfection was examined in PC-3 cells by either ICC with the Par-4 antibody
and secondary antibody conjugated to Alexa Fluor 488 (green fluorescence)
followed by nuclear staining with DAPI (D, left panel) or by staining with FITC
conjugated-Annexin V antibody (D, right panel).

Cells expressing Par-4 or

mutant proteins were scored for chromatin condensation or Annexin V positive
cells indicative of apoptosis by confocal microscopy as described in Materials
and Methods, and quantitative data are shown in panel C. Nomarski images
show

total

number

of

cells

in
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each

field

(D,

right

panel).

Fig. 2.1. T155 is essential for the apoptotic function of Par-4.
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Fig. 2.1. T155 is essential for the apoptotic function of Par-4.
E)

Inhibition of NF-κB transcriptional activity by Par-4 or its mutants (E), PC-3

cells were transfected for 48 h with NF-κB-luc reporter construct and βgalactosidase plasmid together with vector, Par-4 or mutant constructs. Wholecell lysates were subjected to luciferase assays, and luciferase activity was
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Fig. 2.1. T155 is essential for the apoptotic function of Par-4.
F)

PC-3 cells were transiently transfected with expression constructs for

GFP-SAC or GFP-SAC/155A mutant and expression of the mutants was
confirmed by Western blot analysis with the Par-4 or actin antibody
G and H)

The ability of the mutants to induce apoptosis was quantified by

confocal microscopy). In panel H, DAPI has been psuedo-colored red, and the
yellow fluorescence resulting from the overlay with the green fluorescent GFPfusion proteins, indicates nuclear localization.
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Fig. 2.1. T155 is essential for the apoptotic function of Par-4.

46

either condensed DAPI stained nuclei (Fig. 2.1D left panel) or Annexin V positive
cells (Fig. 2.1D right panel). The deletion mutant ∆NLS2, lacking NLS1 and NLS2
that does not translocate to the nucleus (El-Guendy et al., 2003), was used as a
control. We found that the 154A mutant induced apoptosis similar to wild type
Par-4, but the 155A mutant and ∆NLS2 were unable to induce apoptosis (Fig.
2.1, C and D; data for cytoplasmic retention of ∆NLS2 are similar to those
described previously in reference 12, and therefore not shown).

All the

constructs were expressed equally well, as assessed by Western blot analysis
(Fig. 2.1B) and immuno-cytochemistry (Fig. 2.1D); suggesting that lack of
apoptosis by 155A is not due to reduced expression. These findings suggested
that T155 is essential for the apoptotic function of Par-4 and that the T155A
mutation abolishes its apoptotic activity in PC-3 cells.

We then tested whether the functions of Par-4 essential for its apoptotic
activity, such as inhibition of NF-κB transcription were altered by the T155A
mutation. PC-3 cells were transiently transfected with Par-4, 155A mutant, or
∆NLS2 and vector for control and NF-κB-luciferase reporter construct, and
whole-cell extracts were tested for the ability of Par-4 or the mutants to inhibit
NF-κB activity. As seen in Fig. 2.1E, relative to vector, Par-4 inhibited NF-κBdependent luciferase activity but the 155A mutant or ∆NLS2 was unable to inhibit
this activity. A study of the kinetics of inhibition of NF-κB activity and apoptosis
over a 48 h period indicated that, similar to our previous findings (El-Guendy et
al., 2003), inhibition of NF-κB activity by Par-4 preceded apoptosis (data not
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shown as the findings are similar to those reported in reference (El-Guendy et al.,
2003). Moreover, the 155A mutant neither inhibited NF-κB activity nor induced
apoptosis over this time period (data not shown). These findings suggested that
the T155A mutation in Par-4 led to loss of its apoptotic potential.

Next, because the SAC domain of Par-4 was necessary and sufficient for
cancer cell apoptosis by Par-4, we tested whether T155 was crucial for apoptosis
by the SAC domain. The T155 residue in the SAC domain was mutated to 155A,
and PC-3 cells were transiently transfected with the SAC domain construct or
SAC/155A mutant construct and tested for apoptosis induction. Expression of the
constructs was ascertained by Western blot analysis (Fig. 2.1F). As seen in Fig.
2.1 (G and H), the 155A mutant of the SAC domain completely lost its ability to
induce apoptosis in PC-3 cells. The proximity of T155 to the NLS raised the
possibility that phosphorylation of T155 might play a role in nuclear entry of Par4. However, confocal microscopy indicated that the T155A mutant of Par-4 or of
the SAC domain translocated to the nucleus yet failed to induce apoptosis (Fig.
2.1, C & H).

To ascertain that the loss of the apoptotic potential of Par-4 or the SAC
domain resulting from the T155A mutation was not limited to the PC-3 cell
background, we tested the 155A mutant of Par-4 or of the SAC domain in NIH
3T3/Ras cells, as well as in various lung cancer, breast cancer, and prostate
cancer cell lines (see Fig. 2.2, G & H; or Fig. 2.3, B-D). Similar to our findings in
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PC-3 cells, Par-4 or the SAC domain induced apoptosis in all the cells tested but
the Par-4/155A or SAC/155A mutant failed to induce apoptosis in these cells
(also see Figs. 2 and 3). Together, these findings indicated that the T155 residue
is essential for apoptosis by Par-4 or the SAC domain.

PKA phosphorylates Par-4 at T155.
Par-4 protein contains several S and T residues that are potential
phosphorylation sites for PKA, PKC and CKII (El-Guendy et al., 2003). In order to
determine whether regulation of the apoptotic function of Par-4 is linked to
phosphorylation, we determined whether Par-4 is phosphorylated in vivo. NIH
3T3/Ras cells were transfected with the Par-4 expression construct or vector for
control and then metabolically labeled with (32P) orthophosphate. The lysates
were subjected to immuno-precipitation with the rabbit polyclonal Par-4 antibody
or with pre-immune serum as control. The immuno-precipitates were resolved by
SDS-PAGE,

transferred

autoradiography.

The
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immunoprecipitated with the Par-4 antibody (Fig. 2.2A, upper panel) was further
confirmed as Par-4 by subjecting the same blot to Western blot analysis with Par4 antibody (Fig. 2.2A, lower panel). The amino acid context of T155 (KRRST)
suggests that it is a consensus phosphorylation site (RXXS/T) for PKA.
ascertain that Par-4 is indeed phosphorylated by PKA and that Par-4
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To

Fig. 2.2. PKA phosphorylates Par-4 at T155.
A)

Par-4 is a phosphorylated protein, NIH 3T3/Ras cells were transiently

trasfected with vector or Par-4 for 12 h, incubated in phosphate-free medium
overnight, and then metabolically labeled with 200 µCi 32P-orthophosphate for 5 h.
Whole-cell extracts were subjected to immuno-precipitation with Par-4 or control
IgG antibody, resolved by SDS-PAGE, and transferred to PVDF membrane. The
blot was autoradiographed (upper panel), and finally probed with the Par-4
antibody (lower panel).

B)

PKA phosphorylates Par-4 at T155, NIH 3T3 cells were transiently

transfected with vector, Par-4, 154A or 155A expression construct for 24 h and
whole-cell extracts were immuno-precipitated with the Par-4 antibody or IgG
control antibody. The immuno-precipitated proteins were subjected to an in vitro
phosphorylation reaction with purifed PKA enzyme and (γ-32P)-labeled ATP, and
then the radiolabeled proteins were resolved by SDS-PAGE, transferred to PVDF
membrane and autoradiographed. The blot was finally probed with Par-4
antibody to determine Par-4 or mutant protein level.
scanning of the blots, the amount of
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Following densitometric

P-label incorporated into ectopic Par-4 or

mutant protein by PKA was normalized to the corresponding protein level
detected on the Western blots, and relative amount of 32P-label incorporated (i.e.,
PKA phosphorylation) is shown at the bottom of the panel (B).
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Fig. 2.2. PKA phosphorylates Par-4 at T155.
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Fig. 2.2. PKA phosphorylates Par-4 at T155.
C)

PKA phosphorylates Par-4 in vivo , we used 137-187 and 137-187/155A

expression constructs, which were first tested for expression by transient
transfection followed by Western blot analysis with Par-4 or actin antibody (C,
right panel).

To examine whether PKA phosphorylates Par-4 in vivo (C, left

panel), NIH 3T3/Ras cells were transiently transfected with vector, 137-187 or
137-187/155A mutant expression construct in the presence or absence of PKAinhibitory peptide PKI for 24 h, then metabolically labeled and immunoprecipitated with the Par-4 antibody or IgG control antibody.

The immuno-

precipitates were subjected to SDS-PAGE, transferred to nylon membranes and
autoradiographed (C, left upper panel). Finally, the blots were probed with the
Par-4 antibody (C, left lower panel), as described above in panels A and B.
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Fig. 2.2. PKA phosphorylates Par-4 at T155.
D)

To characterize the phospho-T155 (pT155) antibody, MEFs were

transfected with GFP, GFP-Par-4 or GFP-155A plasmids, with or without the
PKAc expression construct for 24 h, and Western blot analysis for phosphoT155, Par-4, PKA catalytic subunit and actin was performed.
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Fig. 2.2. PKA phosphorylates Par-4 at T155.
E and F)

pT155 antibody does not recognize 155A mutant of Par-4. NIH

3T3/Ras cells (E) or PC-3 cells (F), cells were transiently transfected with vector,
Par-4, 154A or 155A plasmids (E & F, left panels), or with GFP, GFP-Par-4 or
GFP-Par-4/155A plasmid and treated for 24 h with vehicle or 20 µM or 40 µM
PKI (E & F, right panels), and then subjected to Western blot analysis with
pT155, Par-4 or actin antibodies.
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Fig. 2.2. PKA phosphorylates Par-4 at T155.
G)

To determine whether inhibition of PKA activity inhibits apoptosis by Par-4,

PC-3, NIH 3T3/Ras or MDA MB 231 cells were transiently transfected with GFP
or GFP-Par-4. The PC-3 transfectants were treated with vehicle, PKI 20 µM or
PKI 40 µM; and NIH 3T3/Ras or MDA MB 231 cells were treated with PKI 20 µM;
and assayed for apoptosis, as described in Fig. 1.

H)

To ascertain that inhibition of PKA activity by PKI inhibits apoptosis by the

SAC domain in diverse cancer cell lines, the cells were transfected with SAC
expression construct and then treated with 20 µM PKI peptide or control and
scored for apoptosis.

I)

To confirm that PKI inhibits PKA activity, PC-3 cells, NIH 3T3/Ras or MDA

MB 231 cells were treated with control or 20 µM PKI peptide for 48 h, and wholecell lysates were tested for PKA activity by using the cAMP-dependent PKA
Signatect Assay kit.
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Fig. 2.2. PKA phosphorylates Par-4 at T155.
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phosphorylation occurs at T155, we performed an in vitro phosphorylation assay
with PKA on Par-4 or mutants immuno-precipitated from NIH 3T3 cells, which are
resistant to apoptosis by Par-4. Relative to endogenous Par-4 (which showed
basal levels of phosphorylation in cells transfected with vector), ectopic wild type
Par-4 and the 154A mutant but not 155A mutant showed elevated levels of PKA
phosphorylation (Fig. 2.2B), suggesting that T155 is a primary site of
phosphorylation by PKA.

We next determined whether Par-4 was phosphorylated at T155 residue
by PKA in NIH 3T3/Ras cells.

Par-4 has putative phosphorylation sites for

several protein kinases throughout its sequence that could potentially
overshadow the phosphorylation of T155. In order to focus on the effect of PKA
on T155 in metabolic labeling experiments, we used a deletion mutant of Par-4
that contained aa 137-187, as an in vivo substrate, in which S154 and T155 are
the only two potential phosphorylation sites. The cells were transiently
transfected with 137-187 or 137-187/155A mutant and subjected to Western blot
analysis to ascertain expression of the constructs (Fig. 2.2C right panel); or to
metabolic labeling, followed by immuno-precipitation with the Par-4 antibody or
control IgG (Fig. 2.2C, left panel). As seen in Fig. 2.2C (upper panel), 137-187
showed phosphorylation that was abolished when the T155 residue was altered
to 155A, suggesting that T155 is the primary phosphorylation site in the SAC
domain. Moreover, when the cells were treated with PKA inhibitory peptide PKI
and then subjected to metabolic labeling followed by immuno-precipitation of
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labeled proteins, we noted that inhibition of endogenous PKA activity with PKI
abolished phosphorylation of 137-187 (Fig. 2.2C, left-upper panel). Western blot
analysis confirmed immuno-precipitation of comparable amounts of Par-4 mutant
proteins with the Par-4 antibody (Fig. 2.2C, left-lower panel).

To ascertain phospho-labeling of the T155 residue of Par-4, we raised an
antibody toward the phospho-T155 residue of Par-4, as described in Materials
and Methods.

To characterize the specificity of this antibody toward the

phospho-T155 residue of Par-4, MEF cells were transfected with GFP, GFP-Par4, or GFP-Par-4/155A mutant plasmid in the presence or absence of a plasmid
expressing the PKA catalytic subunit (PKAc). As seen in Fig. 2.2D, the phosphoT155 antibody recognized a Par-4 band only in transfectants that expressed both
GFP-Par-4 and PKAc, but not in those that expressed GFP-Par-4 in the absence
of PKAc or expressed GFP or GFP-Par-4/155A mutant, indicating that the
phospho-T155 antibody is specific for the phospho-T155 residue of Par-4.

We next used the phospho-T155 antibody to test whole-cell lysates of NIH
3T3/Ras or PC-3 cells transfected with either Par-4 or the 155A mutant of Par-4.
Consistent with the phospho-labeling data, the phospho-T155 antibody
recognized a potentially phosphorylated form of Par-4 only when NIH 3T3/Ras or
PC-3 cells were transfected with Par-4 but not when transfected with the 155A
mutant (Figs. 2 E and F, left panels). Moreover, the phospho-T155 band of Par-4
was abolished when the cells were treated with PKA specific inhibitor PKI; further
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confirming that PKA phosphorylates Par-4 at T155 (Figs. 2 E and F, right
panels). Together, these findings indicated that in cells, such as NIH 3T3/Ras
and PC-3, that are susceptible to apoptosis by Par-4, PKA activity
phosphorylates Par-4 at T155.

Inhibition of PKA activity inhibits apoptosis by Par-4 or SAC domain.
To ascertain that PKA activity is necessary for the apoptotic function of
Par-4, PC-3, NIH 3T3/Ras, or MDA MB 231 cells were transiently transfected
with GFP or GFP-Par-4 construct and treated with either control or PKA inhibitory
peptide PKI. The cells were then scored for apoptosis. As seen in Fig. 2.2G,
PKI significantly (P<0.001) inhibited the induction of apoptosis by Par-4 in all
three cell lines. We also tested whether apoptosis induced by the SAC domain
was regulated by PKI by transfecting PC-3, NIH 3T3/Ras, MDA MB 231, or H157
cells with the SAC domain construct in the presence of control or PKI peptide.
As seen in Fig. 2.2H, relative to control, PKI inhibited apoptosis by the SAC
domain.

To ascertain that PKI indeed inhibited PKA activity, PC-3, NIH 3T3/Ras or
MDA MB 231 cells were treated with PKI or control peptide and intracellular PKA
activity was determined.

As seen in Fig. 2.2I, PKI strongly inhibited the

endogenous PKA activity relative to the control peptide. These findings suggest
that the apoptotic ability of Par-4 is dependent on the presence of active PKA
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enzyme and inhibition of PKA enzymatic activity abolishes the apoptotic ability of
Par-4.

Cancer cells have elevated PKA activity, which correlates with the
apoptotic ability of the SAC domain.
The findings at this stage of the study suggested that apoptosis by Par-4
depends on the presence of an intact PKA consensus site T155 and active PKA
enzyme. Moreover, the differential apoptotic ability of ectopic Par-4 in cancer
versus normal cells raised the possibility that cancer cells may have elevated
basal PKA activity levels compared to normal counterparts. A literature search
indicated that PKA, especially PKA type I, is highly expressed in various
transformed and cancer cells compared to corresponding non-transformed
normal/immortalized cells (Cho et al., 2000; Cho-Chung et al., 2002; Tortora and
Ciardiello, 2002). However, as PKA is a tightly regulated enzyme, it was not
clear whether elevated protein levels of the PKA subunits correlate with elevated
catalytic activity. Therefore, we sought to determine whether PKA activity was
indeed elevated in cancer cells relative to normal/immortalized cells.

We

assayed the enzymatic activity of PKA in several panels of transformed or cancer
cell lines, as well as, their normal/immortalized counterparts. As seen in Fig. 2.3A
(left panel), NIH 3T3/Ras cells showed over 10 fold higher PKA activity than the
immortalized NIH 3T3 parental cells.

A panel of lung cancer cells including

A549, H838, H157, and H460, showed 5-12 fold higher PKA activity relative to
normal primary bronchial epithelial cells NHBE (Fig. 2.3B, left panel). The breast
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cancer cells MCF-7, MDA MB 231 and MDA MB 435 showed 47-82 fold higher
PKA activity compared to normal immortalized mammary epithelial cells MCF10A
(Fig. 2.3C, left panel). A panel of prostate cancer cells including LNCaP, LNCaP
derivative LNCaP/IGFBP5 and PC3 cells showed 4-13 fold higher PKA activity
than normal primary prostate epithelial PrE cells or immortalized prostate
epithelial PZ cells (Fig. 2.3D, left panel). These findings indicated that
transformed or tumor cells had elevated PKA activity relative to the
corresponding normal or immortalized cells.

The apoptotic ability of Par-4 is mediated by the SAC domain with an
intact T155 residue.
susceptibility

to

To test whether elevated PKA activity correlates with

apoptosis

by

the

SAC

domain,

we

transfected

the

normal/immortalized and cancer cells with vector, SAC domain, or SAC/155A
expression construct and assayed for apoptosis 48 h post-transfection.
Interestingly, the SAC domain of Par-4 induced apoptosis only in the cells with
elevated PKA, i.e., in the transformed or tumor cells and not in the
normal/immortalized cells (Fig. 2.3A-D, right panels). By contrast, the SAC/155A
mutant failed to induce apoptosis in the cell lines tested (Fig. 2.3A-D, right panel).
These findings indicated that PKA activity is elevated in transformed/cancer cells
compared to normal/immortalized cells and that elevated PKA activity correlates
with the ability of the SAC domain to induce apoptosis in a T155-dependent
manner. Thus, elevation of PKA activity is a key factor that activates cancer cellspecific apoptosis by Par-4. To test if elevated PKA activity in cancer cells
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Fig. 2.3. Cancer cells have elevated PKA activity.
A-D, left panel)

Whole-cell

lysates

were

prepared

from

various

normal/immortalized or cancer cell lines and in vitro PKA enzymatic assay was
performed using the cAMP-dependent PKA Signatect Assay kit (A-D, left panel).

A-D, right panel)

The cell lines were transiently transfected with vector, GFP-

SAC or GFP-SAC/155A constructs and the transfectants were visualized using
confocal microscopy for GFP fluorescence of Par-4 or mutant constructs and
DAPI staining for apoptosis.

E)

Par-4 was preferentially phosphorylated in cancer cells compared to

normal cells, whole cells lysates from prostate cancer cell lines LNCaP,
LNCaP/IGFBP5 and PC-3, and immortalized prostate epithelial cell line PZ were
subjected SDS-PAGE, transferred to PVDF membranes and probed with
phospho-T155 antibody, Par-4 antibody and finally actin antibody as loading
control.
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Fig. 2.3. Cancer cells have elevated PKA activity.
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Fig. 2.3. Cancer cells have elevated PKA activity.
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correlated with increased phosphorylation of Par-4 in cancer compared to normal
cells, whole-cell extracts of prostate cancer cells LNCaP, LNCaP/IGFBP5 and
PC3 cells along with immortalized prostate epithelial PZ cells were analyzed for
phosphorylation of Par-4 at T155 by Western blot analysis using a phospho-Par4 T155 antibody. As seen in Fig. 2.3E (left panel), when the phospho-T155 Par4 levels were normalized to the total Par-4 levels, the cancer cells showed much
higher levels of phospho-T155 Par-4 compared to the PZ cells. The pattern of
occurrence of phospho-Par-4 correlated with the PKA activities of the cells and
with the ability of the SAC domain to induce apoptosis in the respective cells.
The findings from these experiments indicate that Par-4 is preferentially
phosphorylated in cancer cells at T155 and that the relative extent of
phosphorylation correlates with PKA activity and the apoptotic ability of Par-4 in
these cells.

Enforced elevation of PKA activity in normal cells activates the apoptotic
potential of the SAC domain of Par-4 in a T155-dependent manner.
The above experiments indicated that in addition to nuclear entry, Par-4
must be phosphorylated at T155 by PKA in order to induce apoptosis.
Normal/immortalized cells do not allow Par-4 to translocate to the nucleus and
may

not

contain

adequate

levels

of

active

PKA

enzyme

for

T155

phosphorylation; and are therefore resistant to apoptosis by Par-4.

This

observation of inadequate levels of PKA in normal/immortalized cells is further
supported by the fact that the SAC domain construct is unable to induce
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apoptosis in normal/immortalized cells, despite its predominantly nuclear
localization (Fig. 2.4A). We, therefore, tested whether enforced elevation of PKA
activity in normal cells renders them sensitive to apoptosis by Par-4, SAC domain
or SAC domain/T155A mutant.

To activate endogenous PKA, normal MEFs

were transfected with the Par-4 or SAC domain expression construct and treated
with cAMP analog 8-Cl-cAMP or vehicle as control, and the cells were examined
by confocal microscopy for nuclear translocation of ectopically expressed
proteins and apoptosis. Treatment with cAMP significantly increased apoptosis
by the SAC domain compared to the vehicle-treated cells (Fig. 2.4B). By
contrast, cAMP treatment did not increase apoptosis by Par-4 or SAC
domain/T155A mutant (Fig. 2.4B).

Consistently, cAMP did not alter the

cytoplasmic localization of Par-4, or the nuclear localization of the SAC domain
or SAC domain/T155A mutant (Fig. 2.4A).

Similarly, when MEFs were co-transfected with the expression construct
for Par-4, SAC domain or SAC domain/155A mutant and PKAc, we noted that
the co-transfectants expressing the SAC domain and PKAc underwent apoptosis
(Fig. 2.4, C and D). By contrast, PKAc did not induce apoptosis in conjunction
with vector, Par-4 or the SAC domain/155A mutant (Fig. 2.4D, left panel).
Expression of the constructs was ascertained by Western blot analysis (Fig.
2.4E). Transfection with PKAc construct resulted in an increase in PKA catalytic
activity as seen in Fig. 2.4D, right panel. These findings suggest that neither
Par-4, which fails to enter the nucleus, nor the SAC domain/T155A mutant, which
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Fig. 2.4. Elevation of PKA activity in normal cells activates the apoptotic
potential of the SAC domain of Par-4 in a T155-dependent manner.
A and B)

MEF cells were transiently transfected with vector, GFP-Par-4, GFP-

SAC or GFP-SAC/155A expression constructs, and treated with either vehicle or
8-Cl-cAMP (10 µM) for 48 h and examined for intracellular localization of Par-4 or
mutants (A) or apoptosis (B).
C)

MEF cells were co-transfected with expression constructs for GFP-Par-4,

GFP-SAC or vector, and PKAc for 48 h and the transfected cells were visualized
under a confocal microscope by GFP fluorescence for Par-4 or mutants or by
immuno-staining with PKAc antibody followed by Texas Red-conjugated
secondary antibody, and for apoptosis by DAPI staining .
D, left panel)

Apoptotic cells were scored and the data presented as

percent apoptosis.
D, right panel)

PKA activity was determined using cAMP-dependent PKA

Signatect Assay kit).
E)

Protein expression was examined by Western blot analysis with antibodies

for GFP, PKA catalytic subunit or actin .
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Fig. 2.4. Elevation of PKA activity in normal cells activates the apoptotic
potential of the SAC domain of Par-4 in a T155-dependent manner.
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Fig. 2.4. Elevation of PKA activity in normal cells activates the apoptotic
potential of the SAC domain of Par-4 in a T155-dependent manner.
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Fig. 2.4. Elevation of PKA activity in normal cells activates the apoptotic
potential of the SAC domain of Par-4 in a T155-dependent manner.
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Fig. 2.4. Elevation of PKA activity in normal cells activates the apoptotic
potential of the SAC domain of Par-4 in a T155-dependent manner.
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enters the nucleus but lacks the PKA phosphorylation site, causes apoptosis of
the normal cells in the presence of elevated PKA activity. Thus, the localization
of Par-4 does not depend upon its phosphorylation status, and nuclear
localization of Par-4 is required but not sufficient for ectopic Par-4 to induce
apoptosis.

Exogenous apoptotic stimuli activate endogenous Par-4 to induce
apoptosis in a PKA- and T155-dependent manner.
Our findings thus far suggested that apoptosis by ectopic Par-4 is critically
dependent on the phosphorylation of T155 by PKA. To determine whether
endogenous Par-4 also induces apoptosis in a T155- and PKA-dependent
manner, we used primary MEFs to study the role of the cAMP/PKA pathway in
apoptosis by endogenous Par-4. Consistent with the findings with ectopic Par-4,
endogenous Par-4 in MEFs was predominantly cytoplasmic in localization (Fig.
2.5A). Treatment with cAMP, which induced phosphorylation of the T155 residue
of Par-4 (Fig. 2.5B), did not alter the localization of Par-4 (Fig. 2.5A), and did not
cause apoptosis (Fig. 2.5C). Treatment with low doses of doxorubicin (which do
not elevate PKA levels {Srivastava, 1998}, caused translocation of Par-4 to the
nucleus but did not induce apoptosis (Fig. 2.5, A and C).

Interestingly, co-

treatment with cAMP (to cause phosphorylation of Par-4 at T155 through the
cAMP/PKA pathway) and doxorubicin resulted in translocation of Par-4 to the
nucleus with a significant increase in apoptosis (Fig. 2.5, A & C). Importantly,
apoptosis inducible by this combination of cAMP and doxorubicin was blocked by
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Fig. 2.5. Endogenous Par-4 induces T155- and PKA-dependent apoptosis.
A)

Localization of Par-4 and apoptosis in response to cAMP and doxorubicin

treatment, MEFs were treated with vehicle, 10 µM 8-Cl-cAMP, 100 nM
doxorubicin, 8-Cl-cAMP plus doxorubicin, or 8-Cl-cAMP, doxorubicin, plus 20 µM
PKI and subjected to immuno-cytochemical analysis with Par-4 antibody followed
by FITC conjugated secondary antibody (green). The nuclei were stained with
DAPI (pseudo-colored red) and visualized under a confocal microscope (A) and
scored for apoptosis.
B)

Phosphorylation of T155 by cAMP, MEFs were treated with 10 µM cAMP,

cAMP plus PKI 20 µM, or cAMP plus PKI 40 µM, and whole-cell lysates were
subjected to Western blot analysis with pT155, Par-4, pCREB, total CREB or
actin antibodies (B, upper panel). PKA activity was determined in the lysates
using cAMP-dependent PKA Signatect Assay kit (B, lower panel).
C)

Apoptosis in response to cAMP and doxorubicin, Cells from (A) were

scored for apoptosis as described in Fig. 2.1.
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Fig. 2.5. Endogenous Par-4 induces T155- and PKA-dependent apoptosis.
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Fig. 2.5. Endogenous Par-4 induces T155- and PKA-dependent apoptosis.
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Fig. 2.5. Endogenous Par-4 induces T155- and PKA-dependent apoptosis.
D)

Vincristine induces T155 phosphorylation of Par-4 , HEL cells were treated

with vehicle or 100 nM vincristine for 24 h and 48 h, and Western blot analysis
was performed on the whole-cell lysates with pT155, Par-4 or actin antibodies.
E)

Vincristine-inducible apoptosis, HEL cells were treated with vehicle or

vincristine, in the presence or absence of 20 µM or 40 µM PKI peptide, or
transiently transfected with vector or GFP-Par-4 155A plasmid and assayed for
apoptosis as described in Fig. 2.1.
F)

Effect of the various treatments on PKA activity, whole-cell lysates

prepared from the cells after treatments, as described in panel E, were tested for
PKA enzymatic assay by using the cAMP-dependent PKA Signatect Assay kit.
G)

Inhibition of Par-4 or PKA expression inhibits apoptosis by vincristine, HEL

cells were transiently transfected with 10 µM nonspecific control siRNA, siRNA
for Par-4 or siRNA for PKA α+β duplexes, and then treated with either vehicle or
100 nM vincristine, and assayed for apoptosis as described in Fig. 2.1.
H)

Whole cell lysates from the siRNA transfected cells were subjected to

Western blot analysis with antibodies against PKA catalytic subunits α, β, Par-4
and actin.
I)

Effect of the various treatments on PKA activity, whole-cell lysates

prepared from the cells after treatments, as described in panel F, were tested for
PKA enzymatic assay by using the cAMP-dependent PKA Signatect Assay kit.
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Fig. 2.5. Endogenous Par-4 induces T155- and PKA-dependent apoptosis.
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Fig. 2.5. Endogenous Par-4 induces T155- and PKA-dependent apoptosis.
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inhibiting PKA with PKI treatment (Fig. 2.5, A & C). The efficacy of cAMP or PKI
was confirmed by determining phospho-CREB protein levels by Western blot
analysis (Fig. 2.5B, upper panel) and by assaying the PKA enzymatic activity of
the cells (Fig. 2.5B, lower panel).

Moreover, we studied vincristine for PKA- and phospho-T155/ Par-4dependent apoptosis of primary human fibroblast cell line HEL. Vincristine, a
microtubule inhibitor and widely used chemotherapeutic agent, is a potent
inducer of apoptosis and is known to induce PKA to cause apoptosis (Srivastava
et al., 1998b). As the first step in determining whether vincristine activates T155dependent apoptosis by Par-4, we tested whether vincristine can induce
phosphorylation of Par-4 at T155. As seen in Fig. 2.5D, vincristine treatment led
to an increase in phospho-T155 levels in HEL cells, but total Par-4 levels remain
unaltered. Vincristine treatment induced apoptosis and co-treatment with PKI
resulted in a significant decrease in vincristine-induced apoptosis (Fig. 2.5E),
indicating that vincristine induces PKA-dependent apoptosis. Moreover, ectopic
expression of the 155A mutant of Par-4, but not control vector, completely
abrogated vincristine-inducible apoptosis in these cells. The precise mechanism
by which the 155A mutant serves as a dominant negative to inhibit endogenous
Par-4 function is currently being investigated in our laboratory.

To further ascertain that vincristine-inducible apoptosis was Par-4- and
PKA-dependent, siRNAs targeted against either Par-4 or the α and β catalytic
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subunits of PKA were used to knockdown endogenous levels of the respective
proteins in HEL cells (Fig. 2.5H), and the apoptotic effect of vincristine on these
cells was studied. As seen in Fig. 2.5G, apoptosis inducible by vincristine was
significantly diminished in cells with either siRNA for Par-4 or siRNA for PKA α+β
compared to the nonspecific control siRNA or the untransfected control cells.
Transfection of the siRNA for PKA α+β in the HEL cells led to a decrease in the
basal PKA activity and abolished vincristine-inducible PKA activity (Fig. 2.5I).
PKA activity in cells transfected with control siRNA or siRNA for Par-4 were
similar to the untransfected control indicating that the siRNAs used did not exert
nonspecific effects on PKA activity. Taken together, these findings imply that in
normal cells subjected to an exogenous apoptotic stimulus, endogenous Par-4
induces apoptosis in a T155- and PKA-dependent manner (i.e., similar to ectopic
Par-4 in cancer cells), and that inhibition of either PKA or Par-4 can abrogate
apoptosis.

We also examined the role of PKA- and phospho-T155 Par-4 in the action
of vincristine in lung cancer cells H157. Similar to our observations in HEL cells,
vincristine induced apoptosis in H157 cells and this process was inhibited by PKI,
siRNA Par-4, siRNA PKA α+β or 155A (data not shown).

Thus, vincristine

induces apoptosis by a mechanism that is dependent on PKA and T155 residue
of Par-4 in both normal and cancer cells.
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DISCUSSION
The findings of this study uncover a novel mechanism wherein a procancerous trait, such as elevated PKA activity, is effectively utilized by Par-4 for
selective apoptosis of cancer cells. We noted that cancer cells show a marked
elevation in the enzymatic activity of PKA compared to their normal counterparts;
PKA phosphorylates Par-4 at the T155 residue within the SAC domain and PKAmediated phosphorylation of T155 is critical for induction of apoptosis by Par-4
(Fig. 2.6). Apoptosis by Par-4 requires trafficking of Fas to the cell membrane, to
activate the Fas death receptor pathway, and co-parallel inhibition of cell survival
NF-κB activity; and phosphorylation of Par-4 at T155 is essential for both Fas
trafficking and NF-κB inhibition (this study, and data not shown). The enzymatic
activity of PKA in cancer and normal cells correlates with the phosphorylation
status of Par-4 in these cells and with the susceptibility of the cells to apoptosis
by Par-4. Normal/immortalized cells contain low basal PKA activity and are
unable to phosphorylate Par-4 at T155; moreover, they do not translocate Par-4
to the nucleus, and consequently are resistant to apoptosis by Par-4 (Fig. 2.6).
By contrast, cancer cells that show nuclear entry of Par-4 and have elevated
PKA activity are sensitive to apoptosis by Par-4 (Fig. 2.6). Consistent with this
dual requirement of PKA phosphorylation and nuclear entry for apoptosis, the
SAC domain, which translocates to the nucleus in all cell types, induces
apoptosis only in cancer cells because they show elevated PKA activity. As PKA
promotes survival in various cellular contexts and shows elevated expression
and activity in a broad range of cancer cells, PKA-dependent phosphorylation
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Fig. 2.6. Schematic representation of the PKA- and T155-dependent
apoptosis by Par-4 in normal and cancer cells.
Based on our findings, we propose the following model for differential
apoptosis by Par-4 in cancer and normal cells. PKA activity, which is
constitutively elevated in cancer cells, causes phosphorylation of Par-4 at the
T155 residue.

The translocation of phospho-T155 to the nucleus results in

inhibition of NF-κB activity and apoptosis. By contrast, PKA activity and T155
phosphorylation are relatively low in normal cells and, in addition, Par-4
translocation to the nucleus is blocked by an unknown mechanism.
Consequently, normal cells fail to undergo apoptosis with Par-4. However, proapoptotic stimuli, such as cAMP or vincristine, cause PKA-dependent
phosphorylation of T155; and doxorubicin or vincristine can cause translocation
of Par-4 to the nucleus. Therefore, vincristine alone, or a combination of cAMP
and doxorubicin, can induce apoptosis of the normal cells in a PKA- and T155
Par-4-dependent mechanism. The mechanism of nuclear translocation of Par-4
is currently under investigation.
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Fig. 2.6. Schematic representation of the PKA- and T155-dependent
apoptosis by Par-4 in normal and cancer cells.
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represents a common mechanism for activation of the apoptotic function of overexpressed Par-4 in cancer cells.

The findings of this study implicate the T155 phosphorylation site in the
activation of Par-4-mediated cell death by PKA. T155 flanks the nuclear
localization sequence NLS2 and is conserved in rat, mouse and human Par-4.
An intact T155 site is required for Par-4-mediated cell death and mutation of
T155 to 155A results in loss of apoptosis by ectopic Par-4. By contrast, mutation
of S154, a putative PKA phosphorylation site in Par-4, to 154A, had no effect on
the ability of ectopic Par-4 to induce apoptosis, indicating that T155 was the
primary site of action of PKA in Par-4. Furthermore, inhibition of PKA function
with PKI or PKA expression with siRNAs toward the PKA catalytic subunits,
abrogated apoptosis by ectopic Par-4 or by the SAC domain, suggesting that the
presence of an active form of PKA is essential for apoptosis. Both in vivo and in
vitro assays indicated that the T to A mutation at residue-155 resulted in
significantly diminished PKA phosphorylation of Par-4. On the other hand, the S
to A mutation at residue-154 did not substantially affect the phosphorylation
status of the T155 residue. Only exogenous Par-4 induces apoptosis on its own
in cancer cells, whereas endogenous Par-4 is necessary for apoptosis when cells
are treated with vincristine or cAMP plus doxorubicin (Fig. 2.6).

Similar to

exogenous Par-4, endogenous Par-4 is phosphorylated at T155 in response to
vincristine or cAMP treatment, and induces apoptosis in response to the
exogenous stimuli in a phospho-T155/PKA dependent manner. Together, these
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observations suggest that PKA triggers Par-4 phosphorylation primarily at the
T155 residue.

Several studies have noted that PKA is over-expressed in transformed
cells and in various cancers (Tortora and Ciardiello, 2002). However, because
the activity of PKA is tightly controlled by its regulatory subunit and cAMP, it was
unclear whether this elevation in expression results in concomitant increase in
the enzyme activity. The findings of this study indicated that PKA activity is
significantly elevated in various types of cancer cell lines such as lung, breast
and prostate cancer cells, compared to their normal/immortalized counterparts.
Moreover, there was a direct correlation between the PKA activity of the cells and
apoptotic ability of Par-4 via the SAC domain. Cells with low PKA activity, such
as the normal/immortalized cells, were resistant to Par-4 or the SAC domain; and
cancer cells with elevated PKA activity were susceptible to Par-4 (this study, and
reference (El-Guendy et al., 2003). This observation is further supported by the
recent findings of Dalla-Favera and coworkers that c-myc inducible up-regulation
of the catalytic subunit of PKA (PKAc) is essential for transformation of normal
fibroblasts (Wu et al., 2002). Moreover, stable transfection of normal fibroblast
cells with the PKAc or PKA type I lead to transformation and anchorageindependent colony formation in soft agar (Wu et al., 2002). Several other reports
have shown that free PKAc (also known as extracellular PKA) is elevated and
secreted in several cancers leading to increased cell survival, migration and
metastasis of the cancers (Cho-Chung et al., 2002; Cvijic et al., 2000).
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By

directly activating PKAc, oncogenes can induce the cAMP/PKA signal
transduction pathway in the absence of other cAMP-inducing stimuli. Therefore,
elevation of PKA expression and activity is an integral part of the process of
transformation.

This distinct feature of cancer cells is effectively utilized by

ectopic Par-4 for its own activation and apoptosis induction.

Interestingly,

although endogenous Par-4 is phosphorylated by elevated levels of PKA activity
in cancer cells, it fails to induce apoptosis, suggesting that the apoptotic action of
Par-4 is hindered by an active intracellular mechanism. This constitutive antiapoptotic mechanism directed against endogenous Par-4 is currently under
investigation in our laboratory.

The SAC domain construct was able to induce apoptosis in all cancer cells
tested, but was unable to induce apoptosis in primary normal or immortalized
cells. Because PKA elevation is one of the important features contributing to the
selective apoptotic action of Par-4 in cancer cells, it was conceivable that
enforced elevation of PKA enzymatic activity in normal cells may enable Par-4 to
induce apoptosis in normal cells. Indeed, elevation of PKA activity in normal cells
induced the ability of the SAC domain, which localized predominantly to the
nucleus, to induce apoptosis in MEFs.

By contrast, full length Par-4 is

predominantly localized in the cytoplasm and is unable to induce apoptosis
despite enforced elevation in PKA activity in normal cells. The mechanism for this
selective action of the SAC domain was hitherto unknown. Our findings suggest
that Par-4 phosphorylation at T155 by PKA, as well as, nuclear translocation is
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essential for Par-4 and the SAC domain to induce apoptosis. Cancer cells
susceptible to full length Par-4 have elevated PKA activity for phosphorylation of
T155 and are also able to translocate Par-4 to the nucleus. On the other hand,
hormone-dependent cancer cells, such as LNCaP or MCF-7, are unable to
localize full length Par-4 to the nucleus despite elevated PKA activity; and normal
cells are unable to phosphorylate T155 owing to low PKA levels or to cause
nuclear localization of Par-4. Apoptosis by Par-4, therefore, requires two critical
steps: phosphorylation of T155 by PKA and entry into the nucleus (Fig. 2.6).
Both these steps are feasible for the SAC domain in all cancer cells or for Par-4
in hormone-independent cancer cells, but not in normal cells; thus, accounting for
the tumor selective activation and apoptotic action of Par-4 via its SAC domain.

In summary, ectopic Par-4 is sufficient to induce apoptosis in cancer cells,
whereas endogenous Par-4 is critical for apoptosis induced by vincristine or
cAMP plus doxorubicin. PKA activity is constitutively elevated in cancer cells and
causes phoshorylation of the T155 residue of Par-4. This phosphorylation event
is critical for apoptosis by Par-4. In normal cells, basal PKA activity is relatively
low and phosphorylation of T155 fails to occur; therefore, normal cells are
resistant to apoptosis by ectopic Par-4. Elevation of PKA in normal cells by
cAMP/doxorubicin or vincristine induces apoptosis by a mechanism that is
dependent on PKA-mediated phosphorylation of the T155 residue of endogenous
Par-4. Thus, phosphorylation of the T155 residue of Par-4 by PKA is critical for
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apoptosis. This work provides a novel insight into the mechanism underlying
differential sensitivity of normal and cancer cells.

Copyright © Sushma Gurumurthy 2005
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CHAPTER 3
DISCUSSION AND FUTURE DIRECTIONS

Par-4 is an interesting pro-apoptotic protein that plays a role in apoptosis
in a wide range of cellular contexts involving both physiological and disease
processes. The different localization of Par-4 protein in normal and cancer cells,
as well as the presence of the NLS, NES and LZ domains, and several putative
phosphorylation sites clearly indicate that the apoptotic function of Par-4 is tightly
regulated at multiple levels. It is well documented that the leucine zipper domain
of Par-4 is capable of binding to a wide variety of partner proteins and this
regulates the apoptotic functions of Par-4. However deletion of this region does
not abrogate the apoptotic functions of Par-4 in cancer cells and

interestingly,

leads to constitutive nuclear localization of the Par-4 mutant. These observations
indicate that the C-terminal region plays a predominantly regulatory role in the
functioning of Par-4 exercising control over both cellular localization and
apoptosis function through the NES and hetero-dimerization by the leucine zipper
respectively. The amino acid sequence of Par-4 protein can therefore be divided,
based on function, into the regulatory domain composed of the NES and LZ
domain in the C-terminus and a minimal apoptotic effecter domain composed of
the centrally located NLS2 and the region between aa residues 137-195 called
the SAC domain.
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What regulates localization and activation of Par-4 apoptotic function?
In trying to understand the mechanism by which apoptosis by Par-4 was
activated we built upon two important observations: i) varied localization of
ectopic and endogenous Par-4 in normal vs cancer cells and ii) apoptosis by
SAC mutant preferentially in cancer cells despite strong nuclear presence in the
normal cells. In this study we identified that both endogenous and ectopic Par-4
are regulated by the same mechanism. For Par-4 apoptotic function to be
activated, the minimal apoptotic SAC domain needs to be phosphorylated at
T155 and Par-4 protein should be localized and expressed in the nucleus of the
cell. In an untransformed normal cell, Par-4, both endogenous as well as ectopic,
is excluded from the nucleus, predominantly localized to the cytoplasm and very
poorly phosphorylated at T155 and the cell is maintained in non-apoptotic state.
Under apoptotic conditions, such as with treatment with vincristine, there is
induction of PKA activity, which phosphorylates T155 and translocaties Par-4 to
the nucleus, resulting in apoptosis. Although there are some clues, the
mechanism that controls the localization of Par-4 at the moment is not very clear.
The presence of the NLS and NES in the Par-4 sequence suggests that there is
a dynamic process that shifts between the opposing functions of the NES and
NLS domains. In normal cells, both over-expressed full length Par-4 as well as
endogenous Par-4 is retained in the cytoplasm indicating that the C-terminal
region strongly regulates nuclear exclusion. Deletion of the C-terminal region
relieves the exclusion from the nucleus indicating that this region is essential for
retention of Par-4 in the cytoplasm under normal circumstances. This function is
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probably determined by the nuclear exclusion sequence or the partner protein
bound to the leucine zipper or both. Further studies are required to identify what
relieves the nuclear exclusion of Par-4 in cancer cells and in normal cells
undergoing apoptosis. In contrast to the findings in this study it was noticed that,
in neuronal apoptosis, Par-4 increasingly localized in the post-synaptic density
(PSD) of the synaptosome, away from the cell body and nucleus, during
induction of apoptosis. Although this indicates the criteria for apoptosis by Par-4
may vary with the cellular context, it needs to be verified by our laboratory by
including cell culture models representative of a wider variety of tissue types.

Significance of PKA mediated regulation of Par-4 function
In this study, we identify for the first time that the apoptotic function of Par4 is regulated at the level of the central apoptotic SAC domain. This regulation is
mediated by the phosphorylation of the T155 residue by cAMP-dependent kinase
or PKA, a prolific kinase, a molecule that is active in cells in any given tissue at
any given time. Par-4 regulates several aspects of functioning of a mutli-cellular
organism ranging from embryonic development to tissue differentiation to
maintaining cellular homeostasis. It is possible that this step in activation of Par-4
apoptosis may have evolved as a mechanism to protect tissues in case of
erroneous or excessive PKA signaling. With a discovery that connects PKA and
Par-4, it is now possible to envision a role for Par-4 in physiological apoptotic
settings that may have been overlooked.
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With PKA playing such a variety of apoptotic as well as non-apoptotic
roles, how is apoptosis by Par-4 regulated under specific conditions? All these
functions of PKA are kept in check and appropriately regulated by very tightly
controlling the activation and functional localization of the enzyme. These are
made possible by the development of well differentiated sub-types of the
regulatory subunits and organellar tethering by the different A-kinase anchor
proteins or AKAPs. For example, in an anti-apoptotic function, PKA
phosphorylates and inhibits apoptotic action of mitochondrial protein Bad. This
however, occurs only in response to survival factors and anchoring of type II PKA
to the mitochondria by mitochondrial AKAPs creating a focused subcellular
kinase/substrate interaction (Harada et al., 1999). In contrast, in response to
treatment with microtubule inhibitors such as vincristine, PKA promotes
apoptosis by hyper-phosphorylating and inhibiting its function of Bcl-2, an antiapoptotic mitochondrial protein (Srivastava et al., 1998b). Further studies are
required to understand the complexities of the interaction between PKA and Par4 and the induction of apoptosis. Knowledge of sub-cellular localization of Par-4
and PKA sub-types under varied signaling circumstances is essential. These
studies should include in vitro models of a vast array cells types including
developmental models as well as in vivo models of the same.
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Elevation of T155 Phosphorylation and Apoptosis in Cancers and Other
Diseases
Molecular alterations that promote increased phosphorylation of T155 or
relieve the nuclear exclusion of Par-4 will pre-dispose cells to spontaneous
apoptosis by Par-4. In one of the most exciting findings of this study, we found
that cancer cells show a marked elevation in the enzymatic activity of PKA
compared to their normal counterparts; this is responsible for induction of
apoptosis by Par-4 or SAC mutant in cancer cells. cAMP mediated activation of
PKA is used in the therapy of certain cancers such as certain leukemias and in
combination with retinoic acid in lung and ovarian cancers (Smith et al., 2005;
Srivastava et al., 1998a; Srivastava et al., 1999a; Srivastava et al., 1999b;
Srivastava et al., 2000). If cancer cells already have elevated PKA activity and
phosphorylated Par-4, what is the need to further activate this pathway to induce
apoptosis? It is critical to adequately answer these questions to better
understand the modifications that happen to endogenous Par-4 in these cancers.

While these findings have therapeutic implications for the use of Par-4 or
SAC in the treatment of cancer there may be other disease conditions where
elevated PKA activity can result in deleterious consequences due to activation
apoptosis by Par-4. For example in Alzheimer’s disease (AD), where Par-4 has
been implicated, 30-50% of the cells positive for hyperphosphorylated tau
showed elevation of Par-4 protein levels (Guo et al., 1998). Abnormally
hyperphosphorylated tau protein is associated with poor prognosis in patients
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with AD. Recent studies identified PKA as the kinase that initiates phoshorylation
of the multiple sites of Tau protein (Liu et al., 2004). Together, these findings
suggest that elevated PKA activity may be responsible for hyperphopshorylated
tau as well as activated Par-4 in the neurons of AD. In other diseases like chronic
heart failure, sustained beta adrenergic receptor (AR) stimulation has been
shown to promote cardiac myocyte apoptosis by activation of Ca(2+)/calmodulin
kinase II and PKA (Zhu et al., 2003). In addition to PKA, the T155 site also bears
a consensus site for phosphorylation by calmodulin kinase II. The role of Par-4
apoptosis in cardiac myocytes as well as other disease conditions where PKA or
other kinases that may phosphorylate Par-4 are elevated needs to be
investigated.

Interestingly, endogenous Par-4, despite being nuclear and strongly
phosphorylated at T155, does not induce apoptosis in the cancer cell lines tested
indicating that these cancers have evolved an inhibitory mechanism that possibly
protects the cells from apoptosis by Par-4. The possibility of an interaction
partner that is elevated in cancers, that sequesters and blocks apoptosis by Par4 is currently being investigated in our lab.

This study has made significant advances in understanding the regulation
of Par-4 function at the posttranslational level in normal and cancer cells. As
many questions the findings in this study may have helped answering, there are
as many if not more new unanswered questions that need to be investigated.
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Significance of phosphorylation of T155
The results of this study indicate that phosphorylation of Par-4 at residue
T155 is critical for apoptosis by Par-4. How this phosphorylation event alters Par4 to activate its apoptotic function is not known. Does adding a phosphate moiety
to T155 alter the 3-dimensional structure of Par-4 such that it can interact with
apoptotic effecter proteins? Does this event affect just the core apoptotic domain
from 137-195 or does it have a more global effect on the entire sequence of Par4. This question can be studied by comparing the properties of full length Par-4
with those of the SAC mutant as well as with their respective 155A mutants. A
good starting point would be to study why the 155A mutant of Par-4 inhibits
apoptosis induced by exogenous insults. It has been observed in this study in
vincristine induced apoptosis as well a other studies in our lab, that the 155A
mutant of Par-4 functions as a dominant negative and blocks apoptosis induced
by a wide variety of apoptotic insults. It is not known whether the SAC 155A
mutant behaves similar to the Par-4 155A mutant in abrogating apoptosis
induced by exogenous insults. If it does, this implies that phosphorylation of T155
affects only the region between aa 137-195 and does not have implications on
the entire sequence of Par-4. This question can also be addressed by testing
whether the mutation of T155 to A interferes with the ability of Par-4 to bind to the
known partners of Par-4 such as ζPKC, Dlk or THAP through the leucine zipper
domain. This manner of regulation is seen in the case of p65, a component of the
NF-κB heterodimer. Binding of the C-terminus of p65 to CBP is dependent on
PKA mediated phosphorylation of p65 at a centrally located residue S276.

95

Phosphorylation of p65 at S276 triggers a conformational change in the Cterminal domain that allows interaction between p65 and CBP (Zhong et al.,
1998).

The mechanism by which the 155A mutant protects the cells from
exogenous apoptotic stimuli is another fascinating yet challenging question that
needs to be investigated. One potential mechanism may be that the 155A mutant
binds to endogenous Par-4 via the leucine zipper and prevents its activation by
the signaling pathway initiated by the stimulus. This raises the question of
whether ratios of phosphorylated to un-phosphorylated form of Par-4 are critical
in determining the decision to undergo apoptosis. It is possible that under nonstimulated conditions, the ratio of phospho- vs non-phospho- form of Par-4 is
maintained in favor of the un-phosphorylated Par-4. During apoptosis induced by
external stimuli, the threshold is probably breached when the amounts of proapoptotic T155-phosphorylated Par-4 far outweigh the non-apoptotic nonphosphorylated Par-4 thereby leading to apoptosis. As interesting as these
possibilities may seem, these are difficult to test with a simple experimental
model system. It is, however, important to keep these possibilities in mind and
test them when the opportunity arises in the future.
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Regulation of T155 phosphorylation under physiologic apoptotic
conditions
The results from this study have shown that phosphorylation of the Par-4
T155 residue by PKA activates the Par-4 apoptotic action. Elevated PKA
enzymatic activity in cancer cells therefore activates over-expressed Par-4
leading to apoptosis in these cells.

Normal cells under non-apoptotic

circumstances have low PKA activity and this serves to keep Par-4 in an inactive
form, thereby preventing apoptosis. Par-4 has been shown to sensitize cells to
apoptosis regardless of initiating agent and not all of them are known to activate
the PKA signaling pathway. It is quite possible that T155 may be phosphorylated
by kinases other than PKA under different apoptotic conditions. Examination of
the sequence around T155 (K-R-R-S-T-G-V-V) revealed that T155 could be a
putative phosphorylation site for kinases such as calcium/calmodulin-dependent
kinase II (CaM kinase II) (R-X-X-S/T-V), Ribosomal S6 kinase (RSK) (K/R-X-XS/T). Further studies are needed to identify known or novel kinases that regulate
T155 phosphorylation of Par-4 upon apoptotic stimulation, whether these kinases
differ according to the nature of the stimulus or whether they are common to
apoptosis in general. Another appealing prospect is that Par-4 associates with
phosphatases, maintaining T155 in a de-phosphorylated state of under normal or
anti-apoptotic conditions. Recent studies by the Weinberg group suggest that
loss of phosphatase PP2A is one of the requirements for the cellular
transformation of normal human cells (Rangarajan et al., 2004). It is possible
that, in addition to elevation of PKA enzymatic activity in cancer cells, loss of
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PP2A or a similar phosphatase during tumorigenesis is also responsible for the
increased phosphorylation of T155 and therefore apoptosis by Par-4 in cancer
cells. Another interesting question is whether the leucine zipper domain of Par-4
negatively impacts phosphorylation of T155 if it is bound to an antagonistic
protein. In other words, does the phosphorylation status of T155 of Par-4 depend
on the protein bound to the leuzine zipper domain?

Mechanism of SAC induced apoptosis
It was initially thought that the LZ was critical for apoptosis by Par-4.
However deletion of the LZ had no effect on spontaneous apoptosis by Par-4 in
sensitive cells. Further, the region from 137-195 comprising the SAC domain
proved to be the minimal region of Par-4 that was necessary and sufficient for
apoptosis by Par-4. Although this region of Par-4 is undoubtedly the apoptotic
effecter of Par-4, less is known regarding how this domain causes apoptosis.
Further studies are required to identify the mechanism of apoptosis by this
domain and the SAC 155A mutant can be used as an excellent control in these
experiments. A good place to start would be to identify protein interaction
partners that are unique to this domain of Par-4. The study may be designed to
differentiate between partners that are apoptotic effecter proteins and partners
that bind to a non-apoptotic or dormant form of SAC. Another focus of this study
could be delineating the location of the ultimate site/sites of action of SAC within
the cell. Though the knowledge that the SAC mutant is enriched in the nucleus
has been with us for some time, nothing is known regarding what or how this
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molecule causes apoptosis from within the nucleus. The search for apoptosis
specific SAC binding partners should be designed to identify nuclear specific
candidates and their significance evaluated using knockout or silencing
strategies. Apoptosis is a series of events that engages a number of organelles.
Although the nuclear localization of Par-4 is essential for apoptosis by Par-4 and
the SAC domain is predominantly expressed in the nucleus, there is some SAC
expressed in the cytoplasm. Also one of the better-known mechanisms of actions
of Par-4 is translocation of Fas/FasL to the membrane through the golgi and this
is essentially a cytoplasmic event. Why, then, does Par-4 or SAC have to be in
the nucleus to induce apoptosis? Since the SAC domain lacks the leucine zipper,
the chances of it affecting transcription through protein interaction, such as
interaction with WT1 in the case of bcl-2 down-regulation, seem to be low. One
sub-organelle in the nucleus known to play a role in apoptosis is the PML body.
Par-4 is known interact with two different PML specific pro-apoptotic proteins, Dlk
along with Daxx and THAP, under apoptotic conditions. However, their
interaction is again dependent on the presence of the leucine zipper of Par-4, a
domain that is lacking in the SAC mutant. Given all these details, it seems that
identification of candidate partner or target proteins by which the SAC domain
induces apoptosis will be novel and definitely exciting.

In summary, in this study we identified that activation of apoptotic function
of Par-4 requires two separate events; phosphorylation of T155 residue by PKA
and translocation of Par-4 to the nucleus. Cancer cells are susceptible to
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apoptosis by ectopic Par-4 as cancer cells have elevated levels of PKA
enzymatic activity that effectively phosphorylates T155 in overexpressed Par-4
and can translocate Par-4 to the nucleus, by an unknown mechanism, Normal
cells lack either of these criteria and hence are resistant to apoptosis by Par-4 in
the absence of an exogenous apoptotic stimuli. In normal cells ectopic and
endogenous Par-4 are regulated by a similar mechanism in response to
apoptotic stimuli.

Copyright © Sushma Gurumurthy 2005

100

APPENDIX
LIST OF ABBREVIATIONS
AATF: Apoptosis-Antagonizing Transcription Factor
AD: Alzheimer.s disease.
ALS: Amyotrophic lateral sclerosis.
αMEM: Minimum essential medium.
ATRA: all trans-retinoic acid.
βAPP: Beta amyloid precursor protein.
BP5: Binding protein 5.
cAMP:cyclic adenosine monophosphate
cFLIP: FLICE inhibitory protein.
CKII: Casein kinase II.
CREB: cAMP response element Binding protein
DAP kinase: death associated protein kinase.
DAPI: 4’,6’-diamidino-2-phenylindole hydrochloride.
DISC: death inducing signaling complex.
Dlk: DAP-like kinase
DMEM: Dulbeco’s modified Eagle medium.
DTT: dithiothreitol.
ERK: Extracellular Signal-Regulated kinase.
ES: Embryonic stem cells
FADD: Fas associated death domain protein.
FasL: Fas ligand.
FBS: fetal bovine serum.
FLICE: FADD like ICE (caspase 8).
GFP: Green fluorescence protein.
HEL: Human embryonic lung fibroblast
HEPES: N-2-hydroxyethylpiperazine N’-2-ethanesulfonic acid.
IAPs: Inhibitor of Apoptosis Proteins.
ICC: immunocytochemistry
IGF: Insulin growth factor.
IFNγ: Interferon γ
IκB: inhibitor of κB.
IL-1: Interleukin-1
Jnk: c-Jun N-terminal kinase
kDa: kilodalton
MEF: Mouse Embryonic Fibroblasts
NES: Nuclear exclusion sequence.
NGF: Neuronal growth factor
NF-κB: Nuclear factor-κB
NHBE: Normal bronchial epithelial cells
NLS: Nuclear localization sequence.
Par-4: Prostate apoptosis response 4.
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pCREB: phosphor-CREB
PBS: phosphate buffered saline
PKA: Protein kinase A.
PKC: Protein kinase C.
PKI: Protein kinase A Inhibitor.
PML: Promyelocytic leukemia.
PrE: Prostate epithelial cells
PrS: Prostate stromal cells
PSD: postsynaptic density.
RCC: Renal cell carcinomas.
SAC: Selective Apoptosis-induction in Cancer cells
SDS: sodium dodecylsulfate.
SDS-PAGE: sodium dodecylsulfate polyacrylamide gel electrophoresis.
siRNA: small interfering RNA
THAP: Thanatos-associated protein.
TNF-α: Tumor necrosis factor alpha.
TNF-R: TNF receptor.
TRAIL: Tumor necrosis factor-related apoptosis-inducing ligand
WT1: Wilms’ tumor 1.
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